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 Immunotherapy treatments have been a growing trend for treatment cancer since 2012 
with the first clinical trial for check point blockade therapy to treat melanoma patients. As 
researchers have studied the mechanism of action for immune directed killing of patients’ 
tumors, it is becoming clear how much we need to understand the biology of anti-tumor T cell 
responses to find the characteristics of a robust anti-tumor response. By studying the T cell 
receptor (TCR) repertoire of the endogenous tumor response in mice and patients, we have 
created a tool called ImmunoMap to measure and compare a T cell response by its TCR 
repertoire overtime and even between entirely different T cell targets, while previously only 
individual clonotypes or clones could be tracked. Along with ability to analyze T cell response 
both in research and clinical responses, our work have revealed that neo-antigen T cell response 
comparatively has benefits over self-tumor responses which explains the benefit of targeting 
patient’s cancers based on neo-antigen responses. But not all neo-antigen response show 
immunogenic response to tumors, which lead us to study a model of immunogenic neo-antigen 
response by antigen mimicry between commensal bacteria and a non-self tumor antigen. We are 
excited to show a proof-of-concept in murine melanoma of antigen mimicry in the gut led to a 
boosting of the tumor T cell response and colonization change and prime the T cell response to 
create a therapeutic T cell population. I am pleased with the work I have contributed in the 
Schneck lab, to study what effects the quality of an anti-tumor T cell responses and further 
understand ways to increase positive patient outcomes with immunotherapy treatments against 
cancer.   
Primary Reader and Advisor: Jonathan P Schneck 
Secondary Reader: Jonathan P Powell  
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7 Summary and Organization of the Dissertation  
The organization of the dissertation is as follows: 
Chapter 2 provides an overview of the importance of T cells in the adaptive immune 
response with a description of T cell development, and T cell antigen stimulation. Furthermore, it 
focuses T cell driven anti-tumor responses, the effect of tumor antigens on T cell populations, 
and the role of T cells in cancer immunotherapies.  Finally, it explains the connection between 
the microbiome and the immune system, the impact of the microbiome on immunotherapies, and 
the role of antigens in the microbiome-immune response.  
Chapter 3 is the manuscript: Sidhom, John-William, Bessell, Catherine A. et al. 
“ImmunoMap: A Bioinformatics Tool for T-Cell Repertoire Analysis.” Cancer Immunology 
Research 2 (2018): 151-162. The data and story creates a new analysis tool for TCR repertoires 
of antigen specific T cell populations. More specifically, TCR clones with similar CDR3 regions 
are organized into TCR motifs and by comparing the entire TCR repertoire it is possible to 
observe different anti-tumor responses based on different antigen responses and different 
patients’ responses to immunotherapy.  
Chapter 4 is the manscript: Bessell, Catherine A. et al. “Commensal bacteria stimulate anti-
tumor responses via T cell cross-reactivity.” Unpublished. The data and story center around a 
homologous sequence between the murine tumor neo-antigen KbSIY and commensal bacteria 
sequence “SVY”. Here we confirm the cross-reactivity between the KbSIY and KbSVY 
response.  Furthermore, we show the colonization of the commensal bacteria boosts the KbSVY 
T cell response. This proof of concept approach shows when cross-reactivity occurs between 
commensal bacteria and a T cell response, the microbiome can enhance the anti-tumor response 




Chapter 5 is a summary of my contribution to other projects that have not been put into a 
published manuscript. Here I summarize the major findings and outline further work that can be 






8.1 CD8+ T Cells Function in the Immune System 
Introduction to T cells: The immune system is a complex system organized into an innate 
arm that is composed of fast acting cells and soluble factors that broadly target pathogens, and an 
adaptive immune arm that after initial exposure can create a targeted response toward specific 
pathogens and even cancer cells. The adaptive immune system can create a specific memory 
response to a particular pathogen, which can respond faster and more robustly with secondary 
infection. The innate immune system will have the same speed and response to infections no 
matter the number of exposures to the same pathogen. Within the adaptive compartment, CD8+ T 
cells have both the ability to detect and directly attack infected cells, and as the memory CD8+ T 
cells survey the body they can protect the host over an entire lifetime.  
During initial activation of T cells, a specificity receptor (signal 1) and co-stimulatory 
receptor (signal 2) engagement are necessary to create a robust, and effective T cells response. 
The signal 1 ensures individual T cells that are specific to a particular antigen are activated. An 
antigen is a short peptide sequence, 8-10 amino acid long sequence, which results from cutting 
up larger proteins expressed by pathogens in antigen presenting cells. The T cell receptor (TCR), 
is activated by binding to the combination of antigen that is folded and presented by a MHC 
protein molecule. Along with this signal 1, the signal 2 on an antigen presenting cells bind with 
the receptor on T cells to initiate a signaling cascade to differentiate the cell into an effector T 
cell and proliferate to create daughter cells. The two signals together are essential for optimal 
binding and activation of T cells and without the signaling pathways from each, the threshold of 
activation will not be reached inadvertently. Once a CD8+ T cell is activated, they can traffic 
throughout the host body and when detecting the correct peptide-MHC complex can release lytic 
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molecules to lyse target cells and soluble cytokines that help with an inflammatory response 
against the infection. As T cells protect against a particular antigen, each T cell clone has a 
unique TCR to detect the antigen with specificity. Because each T cell has a unique, a polyclonal 
T cell population made up of multiple clones can recognize the same antigen with their own 
TCRs and within a given infection multiple antigens may be recognized by CD8+ T cells, which 
creates a diverse T cell population even for a single infection. 
T cell Development: T cell development occurs in the thymus, where pre-lymphocytes 
develop into CD4+ and CD8+ T cells, each with a unique TCR. To create the TCR during 
development, T cells will rearrange the DNA at the CDR3 region of the alpha and beta chains of 
the TCR. As the TCR goes through VDJ recombination to create a functioning TCR, CD8+ T cell 
create a range of affinities toward their antigen target. During positive selection, the TCR is 
educated to bind to the host MHC alleles which are the proteins responsible for presenting 
peptide antigens to T cells. During negative selection, if the TCR binds a self-antigen it can be 
deleted or develop into a CD4+ T regulatory T cell. This process of selecting TCRs based on self-
reactivity for limiting the self-reactive T cell response and stop high affinity autoreactive T cells 
from attacking healthy tissue in the body1. Since foreign antigens do not have the same selection 
in the thymus, there is a potential for higher TCR affinities to non-self antigens or mutated 
antigens that no longer respond like self antigens2.  
The negative selection that removes the auto-reactive T cells is referred to as central 
tolerance. After T cell leave the thymus and begin circulating around the body as naïve T cells, 
peripheral tolerance can further inhibit the auto-reactive CD8+ T cells. This is thought to occur 
by presenting the antigen without the presence of co-stimulatory signal and produces a tolerized 
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T cell response or anergic T cell. Anergic T cells have lower T cell activity upon activation and 
future T cell responses from inhibit clones do not response as robustly to their antigen3.  
Creating T cell Antigens and presenting them: The cells responsible for activating T 
cells are termed antigen presenting cells (APCs), cells such as dendritic cells (DCs), B cells and 
macrophages; although all cells (except platelets) express MHC class I for T cells to recognize 
healthy tissue. APCs express the MHC proteins loaded with different short peptide sequences 
that bind to T cells TCRs along with co-stimulatory molecules for activation. Normally, MHC 
class I molecules load ER proteins or irregular formed endogenous proteins that are transported 
into the ER and load into the MHC groove as the protein is expressed. When cells are infected 
with an intracellular pathogen, the viral peptides can be loaded into the MHC class I molecule 
and presented on the surface for activating anti-viral T cells to target infected cells. As healthy 
tissue is infected viral antigens are loaded into MHC class I and the infected cells can be targeted 
by the activated T cell population. In non-infected cells, the peptides from self proteins are 
loaded into the MHC class I molecule and unless presented with co-stimulatory signals does not 
signal an auto-reactive response.  Extracellular antigens can be taken up by APCs by “cross-
presentation,” a cellular pathway that transports proteins inside the cells and into the ER to be 
loaded and presented on the APC cell surface for T cell stimulation. 
The Schneck lab has been a seminal group in the production of artificial APCs, aAPCs, 
which are constructed of a particle platform what has both a signal 1 and signal 2 conjugated to 
the surface and along with supplemental cytokines that can stimulate T cells in vitro for antigen 
specific populations. The aAPC has gone through multiple cycles design, and in the current 
system a paramagnetic nanoparticle can be used to enrich and expand rare, antigen specific T 
cells from the endogenous T cell population in both murine and human system (Figure 8.1)4.  
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Using a Ig molecule with MHC class I molecules a dimer is created that can be actively loaded 
with peptide antigens and along with anti-CD28 or other co-stimulatory molecules to expand 
antigen specific CD8+ T cells for analysis and even for therapeutic settings in murine ACT 





Figure 8.1 aAPCs enrich and expand for antigen specific CD8+ T cells.  
A) aAPCs have a signal 1 peptide-MHC Ig complex and signal 2 anti-CD28 directly 
conjugated to a 100nm iron dextran particle. B) CD8+ T cells are enriched and 
expanded with aAPCs by removing non-specific T cells and directly stimulating the 






Figure 8.2 Adoptive transfer of E&E T cells mediates tumor rejection. 
(Left) Kb-TRP2 and Db-GP100 Enriched + Expanded lymphocytes cultured for 7 days 
prior to adoptive transfer inhibited melanoma growth (p < 0.01 by two-way ANOVA, 8 
mice/group, red). Mice were injected with subcutaneous melanoma 8 days prior and 
irradiated with 500 cGy gamma irradiation 1 day prior. Noncognate E+E lymphocytes 
(SIINF; black) did not inhibit tumor growth (compared to untreated, gray), whereas 
cognate E+E (TRP2+GP100, red) did. (Right) Survival of animals from C. 2/8 mice 
showed complete rejection of tumors in the Kb-TRP2 and Db-GP100 treated group, 
which had significantly longer survival compared to noncognate and untreated groups 
(p < 0.01 by Mantel-Cox). (Figure Taken from5) 
 
 
8.2  T cell Driven Anti-Tumor Immunity 
As tumors develop the immune system has a substantial role to clear premalignant and 
malignant cells. As pre-cancerous cells develop mutations and begin to replicate some of the 
malignant cells grow faster and or turn on pathways to inhibit the immune system to clear the 
tumors6. This immunoediting of the tumor on the immune system shows the interplay between 
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what the immune system can detect and methods to shut off or silence the anti-tumor immune 
response7.  
Tumor Antigens: The T cell population can detect the cancer cells through several 
different antigen types: self antigens (also called tumor associated antigens), cancer/testis 
antigens, and mutated antigens also called neo-antigens8. While each type of antigen can be 
presented if the cancer cells have a functioning processing and presentation machinery, each T 
cell antigen type can have a different ability to detect and respond to their appropriate antigen. 
Self antigens are normal antigens expressed by healthy tissue as well as the cancerous cells. 
MART-1 is a common melanoma CD8+ antigen that is expressed by healthy melanocytes but is 
highly expressed on melanoma tumor cells and MART-1 specific T cells can detect their target 
antigens on tumor cells and lead to clearance in some patients receiving adoptive cellular 
therapy9. As described earlier, self antigens have the pressure of both central and peripheral 
tolerance which can limit both the high affinity clones from entering the circulating T cell 
population and also inhibit the available T cell clones (Figure 8.3). Cancer/testis antigens are 
epitopes that are processed from proteins expressed during limited times in tissue development 
and are not expressed by healthy tissue. The T cell clones that can detect cancer/testis antigens 
can have pressure through central tolerance if those epitopes are expressed in the thymus, but 
unless the tumor cells start expressing this new target, those T cells will not be able to detect the 
tumor. Finally, neo-antigens result from mutations expressed by tumor cells. The majority of 
neo-antigens develop from random point mutations as the cancer grows and accumulates 
mutations, called passenger mutations10.  If the DNA mutation leads to a new peptide sequence 
and section of DNA is expressed, the processed and presented neo-antigen can be detected by the 
antigen specific CD8+ T cell.  If the wildtype sequence does not create a T cell response, the 
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mutated neo-antigen response has the potential for higher affinity clones and has not been limited 
as self-antigen T cell responses (Figure 8.3).  
 
 
Figure 8.3 Tumor specific T cell populations comparison based on antigen type.  
Excising both self reactive antigen T cells present in the tumor or neo-antigen reactive T 
cells may select for personalized therapy instead of established tumor antigen response, 
yet may be higher affinity and function. (Figure adapted from11) 
 
 Comparison of self and neo-antigen tumor responses: By defining both self and neo-
antigen by their ability to detect and activate against tumor cells researchers and clinicians can 
ask: what is the benefit of targeting different tumor antigen types? Asked another way: what are 
the benefits and risks of targeting cancers by the two antigen types? Self antigen CD8+ T cell 
responses although can target healthy tissue, can be activated against the tumor and all the tumor 
cells can potentially express the self antigen. Neo-antigens develop as mutations accumulate in 
the dividing tumor cells, and if a neo-antigen target occurs in one cell of the tumor, the parental 
expansions do not carry the neo-antigen target. This polyclonal expression of neo-antigens in the 
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tumor carries the risk that a neo-antigen response, even if highly productive, will only be able to 
target a portion of the tumor cells. As previously stated, the neo-antigen T cell responses may 
have less central and peripheral tolerance which does not limit the higher affinity or functional 
activity compared to self antigen T cell responses. Yet, the largest road block to robust neo-
antigen targeted T cell responses is the rate of production of immunogenic, neo-antigen targets in 
tumor cells. To identify neo-antigens, tumor cells must be DNA sequenced and compared to 
healthy tissue DNA sequences to identify changes in the amino acid sequence of proteins.  The 
tumor must also be RNA sequenced to determine which possible mutations are expressed in the 
tumor cells. From the potential neo-antigen targets, an algorithm that ranks immunogenic epitope 
sequences by predicted ability to bind a suggested HLA allele for presentation to T cells. 
Depending on the restrictive criteria used for binding prediction, the efficiency of prediction can 
increase but some neo-antigens may not be identified if the binding prediction is only selecting 
for the “high binding neo-antigens”. The predicted neo-antigens are tested for immunogenic 
response, by immunizing mice in murine systems and testing for T cell effector responses12,13, 
and testing for T cell effector responses, using mass spectrometry to identify neo-antigens on 
DCs14,15, or creating a mini-gene approach to express neo-antigen sequencing on patient’s 
endogenous DCs for T cell stimulations11. Although, all methods have revealed CD8+ neo-
antigen responses, groups that have created immunogenic enriched criteria for neo-antigens neo-
antigen T cell responses who have also looked within the CD4+ T cell response have found more 
immunogenic CD4+ T cell responses compared to CD8+ neo-antigen responses13. Even in clinical 
settings, trying to identify potential neo-antigens, the majority of detected neo-antigen response 
are due to CD4+ T cell responses while treating melanoma patients with a cancer vaccines and 
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checkpoint blockade16. Looking at the responses to overall response rate to immunotherapy, the 
neo-antigen targeted response hold promise for patients undergoing immunotherapies.  
Immunotherapies: The expansion of immunotherapies into multiple cancer types shows 
the power of activating the immune system against tumor cells. T cell driven responses against 
cancer has shown long-term beneficial responses, and even after the malignant cells can no 
longer be detected the tumor specific T cells can still be found in patients17. There a few different 
approaches to immunotherapy, I will categorize the approaches as: checkpoint blockade 
therapies, cellular based therapies, and cancer vaccines. Each has their own efficacy and each 
engages the T cell response yet the method of immune activation toward the tumor cells vary. 
Checkpoint blockade therapy (CPB therapy) takes advantage of inhibitory molecules expressed 
by the tumor cells, such as CTLA-4 and PD-L1. Both are ligands expressed on the cell surface 
and engage CD28 and PD-1, respectively, which shuts off T cell activation and effectively 
silences T cell response against their target cell. With administration of α-CTLA4 or α-PD-L1/α-
PD-1 there is an influx of lymphocytes to tumor tissues, and decrease in tumor burden18. It has 
been shown that CPB has increased benefit when PD-L1 is expressed on the tumors, and 
lymphocytes are present in the tumor prior to treatment19. This suggests CPB can re-activate 
previously inhibited T cell populations. Work to identify the tumor antigens responsible for T 
cell response show both self antigen responses and neo-antigen populations are activated by 
CPB20, although cancers that have a higher rate of mutation and potentially more neo-antigens 
have an increased response to αPD-1 therapy21. Since CPB is a pan T cell activator throughout 
the body, T cells can become activated in healthy tissues and lead to toxicities, so even though 
multiple T cell responses can be activated simultaneously without having to identify the antigen 
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targets, there is  a risk of developing massive T cell activation in the gut, skin, pituitary and even 
cardiac tissues22.  
Cellular based therapies directly treat patients with anti-tumor T cells. Classically 
endogenous T cells are collected from the tumors of patient during surgery and the T cells are 
expanded into large numbers and intravenously transferred back into the patient to kill any 
residual tumor cells. This adoptive cellular therapy approach has been used to expand known 
self-tumor antigens such as MART1 reactive CD8+ T cells in melanoma patients but requires 
tumors to have T cells previously trafficked and reside in the tumor before tumor resection23. 
More recent approaches for ACT is to expand potential neo-antigen T cells for cellular transfer24. 
Alternatively, effector T cells can be collected from blood and genetically engineered to express 
a chimeric antigen receptor (CAR), and CAR can recognized a ligand expressed by the tumor 
and the CAR signaling induces T cell activation and killing of the targeted tumor cells. Using 
either endogenous, specific cells or CAR T cells for adoptive transfer requires the antigen to be 
defined on the tumor and the adoptively transferred cells will only target the portion of the tumor 
that expresses the antigen of interest.  
Finally, cancer vaccines have seen an increase in beneficial response in approaches that 
target multiple neo-antigens simultaneously15,16 and has recently showed positive results in 
classically non-immunogenic cancers such as breast cancer25. As with neo-antigen focused 
cellular therapies, neo-antigen tumor vaccines are a personalized therapy for each patient, and 
before beginning therapy the antigen targets must be defined. The vaccines developed usually 
house both CD4+ and CD8+ T cell neo-antigen targets, and responding patients have shown both 
CD4+ and CD8+ response post therapy in melanoma patients16. Further work on the benefit of 
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targeting both CD4+ and CD8+ antigens simultaneously may be beneficial in other immunogenic 
cancers.  
 
8.3 The Microbiome and the Immune System 
The Immune System and the Gut: The symbiotic relationship between the microbiome 
and the immune system supports the maintenance of immune cells around the gut, and the 
bacteria in microbiome that promote the immune system itself26. In germ-free animals, with no 
gut microbiome, the immune cells in the gut lymphoid tissues are severely depleted27–29. 
Alternatively, in genetic knockout mice for IL-22, a key cytokine produced by immune cells 
during gut homeostasis, there is a change in the major classes of bacteria that can colonize the 
gut30. The microbiome supports the immune system by supplying the immune system with 
metabolites for gut barrier maintenance and immune cell population and their function at the 
gut31–33. 
Multiple immune cell subsets are involved in normal gut regulation: innate-lymphoid cells 
activate the epithelial cells to support a proper barrier wall between the lumen and inner walls of 
the gut30,34. α/β and γ/δ T cells surround the gut to defend against bacterial infection35–37. DCs are 
continuously taking up antigens from the epithelial layer secreting bacterial products, as well as 
taking up bacteria directly38. DCs help maintain CD4+ Tregs in around the gut to regulate 
inflammation39,40.  Effector CD4+ T cells defending against infection can create pro-flammatory 
conditions that can cause gut and microbiome dybiosis and lead to irritable bowel diseases39. 
CD4+ T cells can also differentiate at the gut can produce IL-17 and IL-22 directly as well as 
activate the epithelial layer to secrete the key cytokines41. CD8+ effector T cells can develop 
13 
 
around the based on the bacterial strains that are present, and the bacteria seem to be a source of 
both adjuvant and antigen42. B cells in Peyer’s patches around the gut produce IgA, the antibody 
isotype that can transfer across the gut barrier, to bind to bacterial antigens43.  Taken together, 
the different immune cell populations are all present at the gut and form the largest peripheral 
accumulation of immune cells.  
Gut microbiome creates a safe barrier; the gut is responsible for inhibition of the immune 
system and at the same time continuous surveillance of the gut by immune system ensure 
bacterial colonization remains only in the gut lumen. Multiple immune cell types, both pro and 
anti-inflammatory cells differentiate and with dysbiosis of gut, bacteria can break through the gut 
barrier and the immune system can have autoimmunity toward the gut, all of which creates a 
delicate balance between the gut and immune system that surrounds it. 
The Microbiome and immunotherapy: In terms of response to immunotherapy, 
particularly checkpoint blockade therapy (CPB), the composition of the gut microbiome seems to 
correlate with patient outcomes. Multiple groups have shown a distinction in the microbiome of 
responder and non-responder patients44–49, yet there is no one clear mechanism of action between 
increased CPB response and how the bacteria in the gut alter the immune response. In the 
previous section, we’ve discussed the development of the immune response corresponds to the 
development of the microbiome. In some patients, having “healthy gut bacteria” is associated 
with decreased irritable bowel diseases associated with CPB therapy, and the presence of the 
healthy bacteria result in overall better response to CPB46,50. One suggested mechanism of action 
is the bacteria activate DCs by microbial stimulation or metabolites, and DCs then have 
increased trafficking to Peyer’s patches, mesenteric lymph nodes and active T cells to trigger 
antigen responses at other sites51.  By looking at the T cell driven responses from the gut, 
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combinations of bacteria alter T cell activation via DCs activation not only in overall stimulation 
but different unfolding patterns in the DC based protein processing machinery, creating effector 
T cell responses that could be responsible for increased benefit by CPB42,52,53. To summarize, the 
metabolites produced, the adjuvant source or even antigens presented at the gut microbiome 
activate epithelial cells and DCs to produce effector T cell responses that associate with benefit 
to CPB therapy, but the antigens the T cells are responding to have not identified. 
Antigen mimicry and immunogenicity: In the field of autoimmunity antigen mimicry has 
been defined as self-antigen and foreign antigen have enough similarity to activate an 
autoreactive T or B cell by the foreign antigen54. In terms of potential neo-epitope responses in 
anti-tumor targeted therapies we have previously discussed the differences in the overall T cell 
response of neo-eptiopes. Within the neo-antigen T cell response, the immunogenicity of the 
neo-antigen can further define productive neo-antigen target. From a study in pancreatic cancer 
patients, it was observed that the patients surviving diagnosis from 5 years or more did not have 
more neo-antigen response but more potential immunogenic neo-antigens, even without 
immunotherapy interventions55. The group defining immunogenic neo-antigen responses defined 
3 criteria for immunogenic neo-antigens: 1) the mutation increases the ability of the peptide 
sequence to load in the MHC allele, 2) the expression frequency of the mutation in the tumor 
clones, 3) the homology of the mutation sequence with a pathogen56. The first criteria 
corresponds to the stable processing and presentation ability of the neo-antigen because if the 
neo-antigen cannot be presented by tumor cells, the T cells cannot be activated or detect the 
target neo-antigen. The second criteria refers to the fact that mutations develop in the tumor 
overtime, and activated T cells can only detect and lyse the cancer cells that have the particular 
neo-antigen mutation in their DNA. The third criteria refers to homology between a foreign 
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sequence and the neo-antigen peptide sequence that can be stimulated through antigen mimicry 
and the cross-reactive T cells from antigens could target the cancer cells. A few groups have 
been able to show commensal gut bacteria promoting CD8+ T cell responses with potential cross-
reactivity between the bacterial and tumor response45,49,57,58 but showing the presence of the 
bacteria inducing an antigen specific and cross-reactive response will be able to show how the 
mutational landscape of tumors with microbiome antigen mimicry can lead to increased anti-






9 ImmunoMap: A Bioinformatics Tool for T-Cell 
Repertoire Analysis1 
9.1 Introduction  
The advent of high-throughput immune sequencing has allowed scientists and clinicians to 
understand antigen-specific interactions of the immune response with various pathologies from a 
systems-like perspective. TCR sequencing creates a detailed analysis of a polyclonal T cell 
population and study both individual clonal dominance as well as the overall diversity of a T cell 
response. Its initial applications showed the depth and breadth of the T-cell receptor (TCR) and 
B-cell receptor (BCR) repertoire59–62. Further applications of immune deep-sequencing have 
contributed to vaccine development and to tracking disease progression in malignancies63–65. 
Sequencing efforts have improved our understanding of immune responses to cancer, 
characterizing the TCR repertoire of circulating as well as tumor-infiltrating lymphocytes 
(TILs)15,66 and responses to immunotherapies15,67.  With the abundance of new “big data” sets, a 
need has arisen to develop biologically meaningful techniques for analysis of TCR repertoire 
sequences. Current analysis methods fall short of providing an intuitive understanding of the 
immune system repertoire for two reasons. First, as purely mathematical constructs, they focus 
on diversity defined as a function of the number of different sequences and their respective 
frequencies, Shannon entropy, and ignore sequence relatedness68. Second, methods that compare 
different repertoires apply stringent criteria by only comparing exact TCR clonotypes (whether at 
the nucleotide or amino acid level) to assess similarity66,69,70. 
                                                 
1 This chater is reprinted (adapted) with permission from “Sidhom, John W., Bessell, Catherine A., Havel, Jonathan 
J., Kosmides, Alyssa, Chan, Timothy A., and Schneck, Jonathan P. ImmunoMap: A Bioinformatics Tool for T-Cell 
Repertoire Analysis.” Cancer Immunology Research (2017).” 
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However, biological sequence similarity, not identity, is the relevant parameter. Ignoring 
sequence relatedness is a significant omission, becauseTCRs with similar, homologous 
sequences likely recognize related MHC/peptide targets71. Several groups have sought to 
understand the structural aspects of the underlying TCR repertoire through a variety of 
techniques that cluster homologous CDR3 sequences, showing that, indeed, TCRs that recognize 
the same antigen have highly homologous sequences71–73. Although this work highlights the 
relevance and rationale behind analyzing TCR sequence repertoire data via clustering methods, 
we sought to create structural diversity metrics for whole TCR repertoires and not just a single 
motif. To address this, we developed ImmunoMap, which visualizes and quantifies immune 
repertoire diversity in a holistic fashion. ImmunoMap not only enables assessment of similarity 
between TCR sequences, but compares the scope of diversity among different repertoires. Our 
approach combines information about the frequency and relatedness of TCR sequences by using 
a sequence analysis inspired by phylogenetics to determine relatedness among CDR3 sequences 
of an antigen-specific T-cell response, as well as the similarities of a particular TCR repertoire to 
other repertoires for the same antigen specific response.  
We initially trained ImmunoMap on the TCRs used by T cells responding to Kb-TRP2, a 
shared self-peptide tumor antigen, and Kb-SIY, a model neo-antigen, in a model of murine 
melanoma.  ImmunoMap analysis showed that in naïve animals, the response to Kb-SIY was 
highly conserved, with many TCR sequences having high sequence homology, a biological 
observation that we missed when using Shannon entropy calculations. In contrast, the bulk of the 
self-antigen response was comprised of fewer and more distantly related sequences, suggestive 
of central tolerance eliminating dominant T cell clones. The presence of tumor had a differential 
effect on the shaping of the repertoire in the model neo-antigen and self-antigen responses, 
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greatly altering the TCR repertoire of the self-antigen response, with a smaller effect on the 
response to the neo-antigen antigen. The two different TCR repertoire changes suggests that self 
responses are either so diverse because of central tolerance, or that self responses are more 
impacted by pheriphal tolerance and the conservation of the repertoire in naïve settings cannot be 
stimulated at the tumor and alternative clones are present and expandable at the tumor. To 
understand the clinical utility of ImmunoMap, we compared ImmunoMap to Shannon entropy 
analysis of TILs from melanoma patients on anti–PD-1 therapy. Whereas Shannon entropy 
calculations did not find any clinically relevant correlates, ImmunoMap TCR diversity score 
found clinically relevant, predicative TCR signatures in patients who responded to anti–PD-1 
therapy after just 4 weeks on therapy. Thus ImmunoMap proved more effective in finding a 
clinically useful parameter that another repertoire analysis technique could not. Overall, 
observing the pressure of tumor antigen type of T cell repertoires was highlighted by analyzing 
and measuring TCR homology of the CDR3 region as well as looking beyond individual antigen 
specific responses for changes to the entire T cell immune response.  
 
9.2 Results 
9.2.1 Overview of ImmunoMap Algorithms 
Weighted Repertoire Dendrograms: In order to visualize the immune response, we created 
weighted dendrograms (See Figure 9.1Figure 9.1); combining information about sequence 
relatedness with information about sequence frequency. We initially applied this analysis to data 
(from the Adaptive Biotechnologies Data Portal74) on the response of tetramer-sorted human 
CD8+ T cells to cytomegalovirus (CMV) (Figure 9.1Figure 9.1). The distance from the end of the 
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dendrogram branches denotes distance in terms of sequence homology; the size of the circles at 
the ends of the branches denotes frequency of the sequence, and color denotes V usage. 
Sequence distance is determined as a function of global alignment scores (Needleman-Wunsch75, 
PAM10 scoring matrix76, Gap Penalty = 30) between all unique combination of sequences as 
follows:  
 
𝑆𝑐𝑜𝑟𝑒12 = 𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 𝐴𝑙𝑖𝑔𝑛𝑚𝑒𝑛𝑡 𝑆𝑐𝑜𝑟𝑒 (𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 1, 𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 2) 
𝑆𝑐𝑜𝑟𝑒11 = 𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 𝐴𝑙𝑖𝑔𝑛𝑚𝑒𝑛𝑡 𝑆𝑐𝑜𝑟𝑒 (𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 1, 𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 1) 
𝑆𝑐𝑜𝑟𝑒22 = 𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 𝐴𝑙𝑖𝑔𝑛𝑚𝑒𝑛𝑡 𝑆𝑐𝑜𝑟𝑒 (𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 2, 𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 2) 













Figure 9.1 TCR homology of CMV specific T cell population. 
Weighted Repertoire Dendogram visualize relatedness of sequences within repertoire 
along with relative frequency of CDR3 amino acid sequences. 
 
 
Dominant Motif Analysis: In order to parse the many sequences that are detected in antigen-
specific CTL expansion, we sought to perform hierarchical clustering to determine structural 
motifs that dominated the response. Thresholds for sequence homology and frequency were set 
by analyzing the sequences of the naïve B6 CD8+ repertoire, taken from the Adaptive 
Biotechnologies Data Portal. We used these thresholds to define homology clusters based on 
sequence distance and then examined clusters that met a predefined frequency threshold and 






Figure 9.2 TCR Repertoire Dominant Motif Creation 
Figure 2 from immunoMap. 
 
Singular and Novel Structural Clones Analysis: We also defined a “singular structural clone” as 
one that has expanded 10x more than the summation of all other homologous clones in a sample, 
representing a singular solution in “sequence space.”. When comparing two separate CMV-
specific sequencing samples, from different individuals, we defined a “novel structural clone” as 
one that has expanded 10x more than the summation of all homologous clones to it in another 




TCR Diversity Score: To quantify the diversity of the entire TCR repertoire, we created a metric 
to quantify the relatedness of an entire sample; defined as the average mapped sequence distance 
of all unique combinations of sequences in a sample, weighted by number of reads per sequence.  
𝑀𝑎𝑝𝑝𝑒𝑑 𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 =  1 −  
1
1 + [𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒]
 
The TCR Diversity score is bounded between 0 and 1, in which a score of 0 would correspond to 
all TCRs in a response being identical and 1 would correspond to all TCRs being infinitely 
different.  
 
9.2.2 Tumor Exerts Differential Expansion Pressure on Antigen-Specific 
Repertoire  
To understand the clonal diversity of antigen specific responses, CD8+ T cells from naïve 
B6 mice were pooled and expanded against a model neo-eptiope antigen Kb-SIY, or against a 
self-tumor antigen, Kb-TRP2 (180-188), as described in literature4. Briefly, CD8+ T cells were 
enriched and stimulated with nanoparticle artificial antigen-presenting cells (aAPCs) containing 
peptide-MHC-Ig molecules and cultured in vitro for 7 days.  The resultant CD8+ T-cell cultures 
were antigen-specific by both peptide-MHC-Ig staining and cytokine analysis, confirming their 
functional specificity. Initial precursor frequency was also measured in the endogenous 
repertoire and, even though T cells that recognize either antigen could be expanded from naïve 
animals, Kb-SIY antigen–specific T cells had a higher naïve precursor frequency. Antigen-
specific populations were sorted and the CDR3 region of the TCR Vβ chain was sequenced.   
ImmunoMap analysis of Kb-SIY-specific and Kb-TRP2-specific TCRs visualized unique aspects 
of the polyclonal response for both antigens (Figure 9.3).  Kb-SIY CD8+ T cells consisted of 
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clones with homologous TCR sequences; however, the naïve response to Kb-TRP2 was more 
clonal in nature (more high frequency clones) and used more unrelated sequences, each creating 
a distinct clonal variant for antigen recognition. 
  
 
Figure 9.3 Naïve Repertoire to Kb-SIY vs Kb-TRP2 antigens. 
Weighted Repertoire Dendograms where distance of ends of branches denotes sequence 
distance, size of circles denotes frequency of sequence, and color of circle denotes 
specific V beta segment usage. 
 
 
Dominant motif analysis showed that anti-Kb-SIY TCR had fewer, yet richer (more 
sequences per motif), dominant motifs than Kb-TRP2 (Figure 9.4). Kb-TRP2 specific T cells had 
a higher percentage of clones representing singular structural T-cell expansions and they took up 
a larger portion of the overall TRP-2 antigen-specific response (Figure 9.4, bottom). Comparing 
the TCR diversity scores, Kb-SIY stimulated a more homologous response, whereas Kb-TRP2 
had a more diverse response. The response to Kb-SIY had a more conserved V usage, 
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predominantly using V13, whereas the response to Kb-TRP2 exhibited a more diverse use of 
V segments (Figure 9.5).   
 
Figure 9.4 KbSIY naïve TCR repertoire has a more conserved dominant motif, while 
KbTRP2 has a more divergent motifs and creates a larger baseline diversity. 
Top Row – Quantification of Dominant Motif Analysis comparing the number of 
dominant motifs, the number of sequences per motif, the contribution of the sequences in 
the dominant motifs to the response, and the contribution to the response per sequence in 
a dominant motif. Bottom Row – Singular Structural Clone and TCR Diversity analysis 





Figure 9.5 The SIY response uses the same V beta genes, while the self response is more 
varied and is shifted in tumor bearing animals. 




To demonstrate the advantages of the ImmunoMap analysis over traditional analytic 
methods, we calculated Shannon entropies for Kb-SIY vs Kb-TRP2 responses. Shannon entropies 
revealed the diversity of the Kb-SIY response to be higher than that of the Kb-TRP2 response. 
However, because the Shannon entropy is largely determined by the number of sequences that 
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are present in the Kb-SIY response and not their relatedness, it missed the fact that although more 
sequences responded to Kb-SIY, they were more homologous than the fewer sequences that 
responded to Kb-TRP2. Thus, the ImmunoMap TCR diversity score and dominant motif analyses 
reflected novel relatedness-information that could not be seen by conventional Shannon entropy 
calculations. 
 
9.2.3 Tumor Exerts Differential Expansion Pressure on Antigen-Specific 
Repertoire 
Although we know that tumors exert pressure on the immune response, it is not clear how 
this alters the repertoire of responding T cells. The ImmunoMap approach can provide insight 
into the biological impact of tumors on polyclonal T-cell responses and TCR usage by studying 
TCR repertoire changes in the presence of a murine melanoma tumor model (B16SIY) that 
contains the self/tumor KbTRP2 epitope as well as a model neo-epitope KbSIY77. Visualization 
of the TCR repertoire by ImmunoMap analysis showed differential effects of tumors on the 
repertoire of pooled splenic T cells specific for Kb-SIY or Kb-TRP2. The Kb-SIY CD8+ T cell 
repertoire was largely unaltered in response to tumors (Figure 9.6). In contrast, as seen by 
ImmunoMap, the Kb-TRP2 response was not only more clonal, but also used TCR sequences that 





Figure 9.6 The tumor alters the self/tumor antigen response, but leaves the neo-epitope 
response unchanged. 
The presence of tumor does not change the splenic neo-epitope response, but expands for 
certain to cell clones of the self/tumor response. Overlapped weighted repertoire 
dendograms of tumor-bearing vs naïve antigen-specific splenic CD8 responses. Mice 
spleens were pooled from tumor bearing or naïve mice, expanded for antigen and sorted 
for CD8 specificity on day 7. (Red = Tumor-bearing repertoire. Blue = Naïve repertoire). 
 
 
Dominant motif analysis showed that the presence of tumors increased the number of 
dominant motifs in the Kb-SIY response. In contrast, the presence of tumors decreased the 
number of dominant motifs in the Kb-TRP2 response, suggesting directed immune pressure on 
the self vs foreign antigens in the context of tumor (Figure 9.7). Four dominant Kb-SIY motifs 
were conserved between naïve and tumor bearing animals. In contrast, no common dominant 
motifs were shared in the Kb-TRP2 response in tumor-bearing animals compared to the naïve 
response. When examining novel structural clones, the Kb-TRP2 response in tumor-bearing mice 
had more structurally novel sequences that, combined, were a larger portion of the response as 
compared to the naïve response. Selective pressure by tumors on the immune response was also 
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seen in analyzing the V usage between naïve and tumor-bearing animals (Figure 9.5). We saw 
the elimination of the use of V16 in the Kb-TRP2 response, and an increased use of V5. In 
contrast, V usage was conserved in the Kb-SIY response between naïve and tumor-bearing 
animals. Additionally, when examining the effect of tumors on Shannon entropy, we see that 
although maintenance of entropy in the Kb-SIY response and its decrease in the Kb-TRP2 
response generally complement the ImmunoMap dominant motif analysis, Shannon entropies are 
uninformative about the conservation, or lack thereof, of TCR sequence structure in response to 





Figure 9.7 Tumor exposure expands the dominant motifs in the neo-epitope response and 
constricts the self/tumor response. 




9.2.4 Lymphoid Organ-Dependent Differences in TCR Repertoires in Tumor-
Bearing Mice 
We hypothesized that the influence of tumors on the repertoire may also vary depending 
upon the relationship of the lymphoid organ to the tumor site. This was studied by analyzing 
antigen-specific TCR repertoires in the spleen versus draining lymph node (dLN), and tumor 
infiltrating lymphocytes (TILs) in pooled tumor-bearing mice lymph nodes and tumors. 
ImmunoMap analysis revealed that the Kb-SIY repertoire selects for a selected structural motifs 
by comparing T cell compartments closer to the tumor site. This is seen as the richness of 
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dominant motifs decreases, the response contributed by singular clones increases, and the TCR 
diversity score drops as one moves from the spleen towards the tumor. Additionally, the 
structural clones expanded in the spleen, dLN, and TILs are generally conserved, as can be 
visualized by the dendrograms and by tracking dominant motifs in the 3 lymphoid compartments 
(Figure 9.8). In contrast, the opposite trend was seen in the Kb-TRP2 response. Dominant motifs 
between the spleen and draining lymph node were not conserved; we were unable to expand any 





Figure 9.8 Tumor focuses the KbSIY TCR Repertoire but maintains dominant motif overlap. 
Overlapped weighted repertoire dendograms of KbSIY expanded T cells from the spleen, 
draining lymphoid and tumor, (blue = spleen, green = draining lymph node, red = TILs). 
 
 
9.2.5 Analysis of anti–PD-1 Clinical Trial Data Reveals Indicators of Response 
Recent studies have implicated changes in T-cell responses as important in clinical 
outcomes to checkpoint blockade. We therefore applied ImmunoMap analysis to clinical trial 
data (BMS-038) from patients with metastatic melanoma undergoing anti–PD-1 therapy 
(nivolumab). For this analysis, formalin-fixed, paraffin embedded scrapings were taken from 34 
patients, the percentage of TILs estimated as per suggested protocol (Materials and Methods) and 
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CDR3 regions of Vβ-chains sequenced before and while on therapy. The number of TCRs 
sequenced in all samples analyzed was not significantly different.  
ImmunoMap was used to compare the TCR repertoire before and after 4 weeks of anti–
PD-1 therapy. Weighted repertoire dendrograms revealed distinct differences between 
responders and nonresponders. Dominant motif analysis showed that patients who had more 
dominant motifs prior to initiation of therapy had more favorable responses to therapy (Figure 
9.9). Additionally, those patients who had a decrease in their TCR diversity score on therapy had 
more favorable outcomes to therapy. In contrast, no clinically relevant signature could be found 
by Shannon entropy calculations. Thus ImmunoMap analysis was superior in its ability to reveal 






Figure 9.9 TCR Repertoire Analysis of Patients Undergoing α-PD1 (Nivolumab) Therapy 
shows differences in repertoire between responders and non-responders. 
Dominant Motif and TCR Diversity analysis from lymphoctyes collected pre and post 4 




Here we introduce ImmunoMap, a bioinformatics approach to analyze TCR repertoire 
sequence data based on beta chain CDR3 sequence overlap, and used it to characterize repertoire 
changes in responses to model murine tumors and in patients undergoing immunotherapy for 
melanoma. By combining information about sequence relatedness and frequency, ImmunoMap 
allows an intuitive appreciation of TCR repertoire characteristics that reconciles the structure and 
function of the repertoire.  
ImmunoMap analysis comparing model neo-antigen (Kb-SIY) and self antigen (Kb-TRP2) 
showed distinct differences in the naïve repertoire to these two different antigens. Although 
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interesting, the conclusions of this analysis cannot be expanded to all foreign vs self-antigens. 
The presence of multiple dominant motifs in the Kb-TRP2 response in combination with greater 
clonality of motifs suggests that central and peripheral tolerance mechanisms limited the clonal 
responses.  Shown by distinct and more frequent clones occupying a larger portion of the 
expanded TRP2-specific repertoire. High affinity self-reactive clones that would produce a 
dominant motif during T cell expansion, with TRP2-specific TCRs would either be removed 
during central thymic development or tolerized in the periphery, explaining the inability to find 
more numerous TCR sequences per dominant motif78–80. Because our analysis was conducted on 
expanded antigen-specific populations, our results demonstrate the “expansion potential” of the 
antigen-specific T-cell repertoire for a model neo-antigen and shared tumor antigen in the setting 
of both naïve and tumor-bearing animals.  It is possible that the limited TCR relatedness of TRP2 
responses could be due to the lower precursor frequency in naïve animals, and the T cells that 
have the ability to expand do not cluster in the same dominant motif due to lower initial cell 
frequency. The impact of pooling animals prior to expansion and sequencing must also be 
considered.  In this scenario, one could be selecting for “public” clones and possibly enriching 
for these parts of the repertoire over “private” clones, unique to each animal and observing a 
diverse motif of expanded KbTRP2 TCRs suggests the T cell population has been tolerized. 
Although individual mice are genetically identical, VDJ recombination occurs as an independent 
process in each animal and the primary TCR repertoire capable of responding to a given antigen 
could vary between individual animals yet by looking for clones with expansion ability we are 
selecting for the dominant, public clones. Therefore, the effects on shaping of the repertoire for 
self and neo-antigen antigens may be most relevant to “public” or conserved sequences. Finally, 
the higher TCR diversity score of Kb-TRP2 alongside with the higher number of dominant motifs 
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suggests that the immune system has created multiple CDR3 sequences to bind to cognate 
antigen/MHC complex. With the high-affinity CDR3 sequences are removed from the repertoire, 
the alternative antigen specific CDR3 sequences have lower affinity but may not share structural 
similarities.  
Although prior work on TCR clustering has focused on understanding the structural 
aspects that confer antigen-specificity71,72, the effects of perturbations to the immune system on 
antigen-specific responses has not been studied. With ImmunoMap, we studied the changes in 
repertoire in response to tumor. We observed that the effects of tumor on the anti-self-Kb-TRP 2 
peptide repertoire indicate that tumors exert greater pressure on the self- than on the foreign-
antigen. Not only did the presence of the tumors correlate with an increase the clonality of the 
response to self, via decreases in the number of dominant motifs and increases in their 
contribution to the net response, but tumor-bearing mice could shift their response to different 
motifs. Additionally, the differences in repertoire characteristics among various lymphoid organs 
for the two different model antigens indicates that tumors effectively eliminated the expansion of 
certain clones from its microenvironment. The consequences of these findings are relevant to 
both antigen-discovery and targeting for immune therapies related to treating cancer. Due to 
limitations of personalized antigen-specific therapy, targeting shared antigens like MART1, a 
self-antigen specific for melanocytes, has been a mainstay of antigen-specific cancer 
immunotherapy81–83. This approach has typically relied on TCR transgenic models in which a 
single TCR clone is chosen as the source for the antigen-specific receptor84–86. Given our 
analysis, several problems with this approach become apparent: (1) antigen-specific expansion 
not only generates a diversity of TCR sequences but one that spans the entire sequence distance 
of the naïve repertoire, (2) self-antigen expansion represents a limited repertoire and arsenal 
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against a given epitope due to effects of tolerance, and (3) the tumor can exert pressure on the 
self-antigen–specific immune response in a more profound way than in the case of a foreign 
antigen. Our findings call into question the approach of using self or over-expressed antigens as 
targets for immune therapy and highlight the importance of exploring responses to neoantigens, 
novel MHC-specific epitopes that arise from mutations in a patient’s individual malignancy21,87–
89. 
We also have used ImmunoMap algorithms to understand mechanisms of successful 
immune responses to cancer against 4T1, a murine breast cancer model89. In that model, when 
analyzing TILs from animals treated with anti–CTLA-4, radiation, or the combination of these 
therapies, we found that the TCR structural repertoire before therapy from TILs was highly 
conserved, seemingly targeting a single antigen, whereas after combination therapy,  the 
structural response broadened within the TILs and each individual animal developed its own 
uniquely expanded repertoire.  
Finally, we used ImmunoMap to study TILs from clinical trial specimens to determine if 
structural diversity is an important parameter in determining successful immune responses to 
cancer immunotherapy. Our analysis revealed that patients who had more dominant motifs prior 
to therapy responded more favorably to therapy. Additionally, the change in TCR diversity 
suggest that patients who respond to therapy converge on a solution of successful TCR 
sequences and thus their repertoire is actually less diverse after therapy. In contrast to previous 
work by Madi et. al that demonstrated a structural broadening of the peripheral repertoire to 
anti–CTLA-4 therapy in melanoma patients, but did not correlate this finding with response, we 
focused our analysis on studying changes in the repertoire within the TILs and could determine 
structural signatures of response73. Although our findings are significant, we note the scope of 
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the clinical trial was limited, which impacted the distribution of clinical responses. Nevertheless, 
taken together, ImmunoMap analysis revealed that patients with a broader repertoire prior to 
therapy have a higher probability of expanding effective TCR sequences and converging on 
selected TCR clones on therapy.  
ImmunoMap not only has potential for the clinical monitoring of patients on therapy, 
through predictions of their likelihood to respond, but enables the acquisition of biological 
insights about antigen-specific immune responses that could alter current immune therapies.  
 
9.4 Conclusion  
In conclusion, we have created a new method to analyze the polyclonal TCR repertoire of 
antigen specific T cell responses. Instead of monitoring individual clonotypes of a T cell 
response, the entire polyclonal response and the frequency of multiple clones gives a more 
detailed description of the overall T cell response. By using the ImmunoMap algorithm to 
categorize similar TCRs, TCR motifs structures can be identified for groups of T cell clones and 
create quantitative comparisons between entire T cell repertoires. Using this approach, we have 
shown different tumor antigens change their TCR motifs structure suggesting immunoediting of 
the tumor upon anti-tumor T cell responses on self tumor antigens but the foreign antigen 
remains unchanged.  Also, ImmunoMap analysis tool to create T cell diversity as a biomarker for 
immunotherapy response and hopefully identify a predictive marker of response based on initial 




9.5 Experimental Methods 
Mice: C57BL/6j mice were purchased from Jackson Laboratories (Bar Harbor, ME). All mice 
were maintained according to Johns Hopkins School of Medicine IACUC 4-5 mice (gender and 
age matched) were used and pooled for each stimulation condition, based on previous T-cell 
expansion experiments, and each stimulation and sequencing run was performed once. Mice 
were randomly selected for naïve or tumor-bearing treatments and principal investigator was 
blinded to which mice received tumors. Murine experiments for naïve and tumor-bearing spleens 
were duplicated in separate pools of animals to demonstrate reproducibility of antigen-specific 
repertoire characteristics (Supplementary Fig. S7).   
Preparation of MHC-Ig dimers and nano-aAPC: Soluble MHC-Ig dimers, Kb-Ig, was prepared 
and loaded with peptides as described90. Nano-aAPC were manufactured by direct conjugation of 
MHC-Ig dimer and anti-CD28 antibody (37.51; Biolegend) to MACS Microbeads (Miltenyi 
Biotec) as described previously91.  
Lymphocyte isolation:  Mouse lymphocytes were obtained from homogenized mouse spleens 
after hypotonic lysis of RBC. Cytotoxic lymphocytes were isolated using a CD8 magnetic 
enrichment column from Miltenyi Biotec (Cologne, Germany) following the manufacturer’s 
instructions. Lymphocytes from lymph nodes were obtained from homogenized inguinal lymph 
nodes and enriched with nano-aAPCs and plated for 7 days. For tumor-bearing animals, murine 
melanoma cell line B16-SIY, obtained with the consent of Tom Gajewski (The University of 
Chicago, IL, USA) through Charles Drake in 2011, and re-authenticated in the past year by flow 
cytometry, was injected subcutaneously after 5 days of culture, measured by calipers and 
harvested when tumors reach over 50mm2. The B16-SIY cell line is a tumor model modified to 
express SIY, a completely foreign epitope to the murine B6 background. In naïve mice setting 
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experiments, it was used as a model foreign antigen such as would be a viral epitope and in 
tumor-bearing animals serves as a tumor antigen. Tumor-infiltrating lymphocytes were obtained 
from tumors by manual digestion and washing, a density gradient centrifugation (Lympholyte 
Cell Separation Media, Mouse, Cedar Lane), and then tumor cells plated for 3 hours at 37°C and 
lymphocytes washed off and plated with nano-aAPCs (1.25x109 particles/mL). All cell lines 
underwent testing for mycoplasma contamination. 
Enrichment and expansion: Nano-aAPC were stored at a concentration of 8.3 nM (5 x 1012 
particles/mL), and all volumes refer to particles at this concentration. Ten million CD8+-enriched 
lymphocytes at ~108 cells/mL were incubated with 10 L of nano-aAPC for 1 hr at 4 °C, for an 
approximate bead:cell concentration of 5000:1. Cell-particle mixtures were subsequently passed 
through a magnetic enrichment column, the negative fraction was collected and the positive 
fraction eluted. Positive fractions were mixed and cultured in 96-well round-bottom plates for 7 
days in complete RPMI-1640 medium supplemented L-glutamine, non-essential amino acids, 
vitamin solution, sodium pyruvate, β-mercaptoethanol, 10% FBS, ciproflaxin, and 1% T-cell 
growth factor, a cytokine cocktail derived from stimulated PBMC as described in92, in a 
humidified 5% C02, 37 °C incubator for 1 week. Specificity of CTLs was monitored on day 7, by 
FACS analysis following LIVE/DEAD cell stain (Thermo Fisher), anti-CD8 (BD Pharmingen, 
Cat# 553035, 53-6.7), and dimeric MHC-Ig staining. The number of antigen-specific cells was 
calculated by multiplying the number of total T cells by the fraction of CD8+ and antigen-
specific T cells; the fraction of antigen-specific cells was calculated after subtracting the non-
cognate MHC staining from cognate MHC staining. 
Sorting and sequencing of antigen-specific CD8+ T cells: Following LIVE/DEAD cell stain 
(Thermo Fisher), anti-CD8 (BD Bioscience), and dimeric MHC-Ig staining, cells were sorted by 
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gating on cells with cognate Dimeric MHC-Ig staining over non-cognate staining. Antigen-
specific CD8+ T cells were sent directly for CDR3 β-chain sequencing by Adaptive 
Biotechnologies.  
In vitro nano-aAPC functionality assay: 7 days following enrichment and expansion antigen 
specificity is confirmed by intercellular cytokine staining. Briefly, RMA-S, given by Michael 
Edidin (Johns Hopkins University, MD, USA) in 1996 (reauthenticated in the past year by 
peptide stabilization assays and cultured for 7 days prior to use) are peptide pulsed (10 M) 
overnight at room temperature with relevant or no peptide and mixed 1:2 RMAS:T-cell ratio 
with expanded T cells. Unpulsed RMAS cells were used as background stimulation. After 6 
hours, cells were washed twice with FACS wash buffer and then stained with viability dye and 
anti-CD8 for 20 minutes. Cells were then fixed and permeabilized with the Cytofix/Cytoperm kit 
(BD Biosciences) following the manufacturer’s protocol. Anti-TNFα (Biolegend, Cat# 506324, 
MR6-XT22) was added to the cells and stained for an hour. 
Precursor frequency assessment: On day 0 following CD8+ T-cell isolation from splenic cells, 
CD8+ T cells were stained with LIVE/DEAD cell stain (Thermo Fisher), anti-CD8 (BD 
Bioscience), and dimeric MHC-Ig staining viability stain with either unloaded or peptide-loaded 
MHC-Ig.  Cells gated on Live cells and anti-CD8a+ staining. 
Collection of TILs from patients undergoing α-PD1 therapy: Eighty-five patients, providing 
written consent, were accrued to a multi-arm, multi-institutional, institutional-review-board-
approved, prospective study (BMS-038) to investigate the pharmacodynamic activity of 
nivolumab. All patients received nivolumab (3 mg/kg Q2W) until progression for a maximum of 
2 years. Tumor samples were collected prior to and four weeks after initiation of nivolumab 
therapy. The samples were stored in RNAlater®(Ambion). 34 patients permitted TCR 
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sequencing, and DNA was extracted and submitted to Adaptive Biotechnologies for survey level 
TCR β-chain sequencing93,94. Clinical response was assessed via CT scan after 24 weeks of 
therapy. 
Deconvolution methods: Due to the fact that animals were pooled together on day 0 prior to 
expansion of antigen-specific cells, there was only one sequencing run. In order to determine the 
variance of calculated indicators of the repertoire, the reads from the sequencing file were 
randomly distributed into the number of bins corresponding to the number of animals that went 
into the experiment. This method of random deconvolution assured that the variance of the 
indicator by random chance was not greater than the difference observed between conditions. 
Weighted repertoire dendrograms:  For the antigen-specific sequencing, productive sequences 
with a frequency > 0.01% were taken for analysis. For anti–PD-1 clinical trial analysis, Adaptive 
Biotechnologies’ files were first filtered to only include sequences with reads greater than or 
equal to 5 and then top 40% of response was taken for analysis. Sequence distances were 
calculated based on sequence alignments scores using a PAM10 scoring matrix and gap penalty 
of 30. Distance matrix was used to create a dendrogram using the Bioinformatics toolbox in 
MATLAB. Circles were overlaid at the end of the branches corresponding to the CDR3 
sequences with diameters proportional to the frequency of the sequence. When using the 
terminology “weighted repertoire dendrogram,” this does not infer that the distance matrix used 
to create the dendrogram is weighted; rather, the dendrogram is visually ‘weighted’ by 
frequency. 
Dominant motif analysis: Using the cluster function in MATLAB toolbox, dendrogram was 
divided into homologous clusters using a homology threshold obtained from analyzing an 
unexpanded adult CD8+ T cell population from a C57BL/6 animal (Supplementary Fig. S1). 
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Clusters whose average sequence distance within cluster <= threshold and met a certain 
frequency cutoff (3% - Supplementary Fig. S1 were denoted as “Dominant Motifs.” Cluster 
frequency was lowered to 1% for α-PD1 clinical trial analysis but held consistent across all 
patients due to the fact that this was not a single antigen-specific population of cells.  
Singular and novel clone analysis: In order to define singular clones, a matrix was setup to 
calculate the mapped sequence distance of every unique combination of sequences in the 
repertoire. Using standard matrix operations within MATLAB, a singular clone was defined as a 
clone whose frequency was 10x the sum of all other homologous clones. Homologous clones 
were those who had a sequence distance determined from the dominant motif analysis. In order 
to define novel clones, the same approach was used, but the matrix was setup in that it calculated 
the mapped sequence distance of every unique combination of sequences between the two 
repertoires being compared. A novel clone was defined as a clone whose frequency was 10x the 
sum of all homologous clones in the other sample.  
TCR diversity score: This measurement of diversity was calculated in a similar method as the 
singular & novel clone analysis. An initial matrix is created where the mapped sequence distance 
is calculated for every unique combination of sequences in the repertoire. Then the average of 
the unique combination calculations is taken, weighted by reads, and reported as the TCR 
diversity score. Additional details of the algorithm behind this calculation are shown in 
Supplementary Fig. S6.   
Shannonntropy calculations: Calculation of Shannon entropy was completed by the following 
formula where pi represents the frequency of each amino acid sequence and n represents the total 








Statistical methods:  No specific statistical method was used to determine sample size for the 
stimulation cohorts. Two-tailed t-tests were used as provided by GraphPad Prism 5 software for 
all comparative statistics given we expect normal distributions across all experiments.  
Code availability: In order to use the ImmunoMap algorithms, we have developed a MATLAB-
based Graphical User Interface (GUI) that can be found along with the source code at 
https://github.com/sidhomj/ImmunoMap. Supplementary Fig. S8 demonstrates the use of the 
GUI. 
Data Availability: TCR β-chain sequencing raw data for the murine experiments is found in 







10 Commensal bacteria stimulate anti-tumor responses via 
T cell cross-reactivity 
10.1 Introduction 
The basis for differential patient responses to cancer immunotherapy involves many 
biological processes including: genetic variability amongst different patients, differences in 
tumor mutational load, and differential microbiome composition. Higher tumor mutational load 
is correlated with beneficial responses to checkpoint blockade outcomes in melanoma and non-
small cell lung carcinoma17. Mechanistically mutations in the tumor can result in novel peptides, 
called neoantigens, which can be targeted by T cells. These neoantigen specific responses are 
critical for tumor clearance after checkpoint  blockade immunotherapy (CPI)14,95. In addition to 
the quantity of potential neoantigens, several studies have also considered their “quality” to help 
identify which patients will be responsive to CPI55,56. 
Another important parameter for patient outcome is the gut microbiota. Responders to 
checkpoint blockade have a different gut bacterial composition than non-responders49,96, 
however the potential mechanisms underlying antitumor effects are unclear. Evidence has 
emerged that the gut microbiota modulates the efficacy of various tumor therapies possibly by 
engaging the innate and/or adaptive immune systems97,98,10. Retrospective analysis of pancreatic 
cancer long-term survivors revealed that some high quality neoepitope responses bear sequence 
homology with pathogenic or commensal bacteria56. However, the effect of homologous epitopes 
between the tumor and microbiota on T cell populations is unknown. Therefore, identifying 
antigens expressed by microbiota and their potential cross-reactivity with T cells recognizing 
tumor-specific neoantigens will provide insight into tumor-reactive T cell populations that can be 
activated by cancer immunotherapy. However, mechanistic studies must address how cross-
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reactive T cell populations react to tumor cells and the effect of bacterial colonization on the 
cross-reactive T cell populations.  These studies will provide insight into how antigen mimicry 
between the commensal bacteria and tumor antigens can lead to beneficial anti-tumor responses. 
Here, we identify an epitope, SVYRYYGL (SVY), found in the B. breve genome with 
homology to the tumor model neoepitope antigen SIYRYYGL (SIY) expressed in B16.SIY 
tumors. Molecular dynamics simulations show that SVY peptide loaded on the murine H2-Kb 
MHC binds to a model TCR specific for the KbSIY complex, the 2C transgenic TCR but with an 
altered configuration. Heterogeneous CD8+ T cell populations, expanded from wild type 
C57BL/6 animals specific for either SIY or SVY, cross-react with both the bacterial and tumor 
antigens. Indeed, Bifidobacteria colonization, as seen by differences in C57BL/6 mice obtained 
from different suppliers, Jackson versus Taconic, boosts expansion of SVY specific T cell 
populations in vitro and differences in commensal bacteria influence the SVY population in vivo. 
In addition, immunization of Taconic mice with the SVY antigen led to activation of SVY-
specific T cells that cross-react and kill SIY-pulsed target cells in vivo. Furthermore, C57BL/6 
mice, obtained from different commercial sources, have differences in their anti-tumor response 
to B16.SIY tumors which grew more slowly in Jackson than Taconic mice. C57BL/6 mice also 
have an altered TCR repertoire dependent on their source. Finally, in an adoptive cellular therapy 
(ACT) treatment model, SVY expanded T cells target SIY-expressing tumor cells in vivo, inhibit 
tumor growth, and extend survival. These studies, for the first time, mechanistically identify that 
commensal bacteria can augment anti-tumor immunity by amplifying T cells that cross-react 






10.2.1 B. breve Contains a Peptide Epitope (SVY) that is Homologous to the SIY 
Epitope 
To identify commensal bacteria epitopes that may influence the B16.SIY anti-tumor 
response, we conducted a search of microbial genomes with the Basic Local Alignment Search 
Tool (BLAST) using the SIY peptide sequence as the query. Genetic alignment (Figure 10.1, a) 
identified a single peptide sequence, SVYRYYGL that varies by only one amino acid from the 
murine H2-Kb MHC restricted model neoepitope “SIYRYYGL” (SIY), [valine (Val) versus 
isoleucine (Ile) at position two].  The SVY epitope sequence, derived from the B. breve 
exopolysaccharide biosynthesis protein, has a 126-fold stronger predicted binding constant for 
H2-Kb compared to the next highest predicted epitope sequence from the EBP protein (Figure 
10.1, a). Processing of the B. breve in vitro was studied by incubating heat-killed B. breve with 
splenocytes and the resultant antigen-specific T cell expansions were analyzed (Figure 10.1. b). 
By day eleven, approximately 3.5% of CD8+ T cells were cross-reactive with the H2-Kb SIY 
complex (KbSIY) (Figure 10.1, b).  In contrast, a control commensal bacterium, Lactobacillus 
rhamnosus, did not stimulate a KbSIY cross-reactive response. Thus, B. breve expresses an 
antigen that can be processed and presented and stimulate KbSIY cross-reactive CD8+ T cells.   
Processing of the B. breve bacterium in vitro was studied by incubating heat-killed B. 
breve with splenocytes and the resultant antigen-specific T cell expansions were analyzed 
(Figure 10.1, b). By day eleven, approximately 10% of CD8+ T cells were cross-reactive with 
the H2-Kb SIY complex (KbSIY).  In contrast, a control commensal bacterium, Lactobacillus 
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rhamnosus, did not stimulate a KbSIY cross-reactive response. Thus, B. breve expresses an 




Figure 10.1 Commensal bacteria Bifidobacterium breve harbors the CD8+ T cell epitope 
SVY. 
A) Genetic map of B. breve, highlighting the homology of a peptide derived from B. 
breve exopolysaccharide biosynthesis protein (EBP) to the model epitope KbSIY. Listed 
in the table are the top three predicted H2-Kb restricted epitopes from the EBP protein 
using the Immune Epitope Database (IEDB) prediction algorithm. (B) Jackson C57BL/6 
mice splenocytes and mesenteric lymph node cells were cultured with or without heat-
killed bacteria and tested for SIY-specific T cell expansion by staining with SIY peptide 
loaded-Kb-Ig dimer on day 11. Live, CD8+ lymphocytes were analyzed by flow 
cytometry for KbSIY binding, frequency determined by subtracting unloaded Kb-Ig 
staining frequency. Error bars indicate SEM. p-value = 0.011 by One-way ANOVA and 
Dunnett’s post-hoc test for multiple comparisons. N=7. (C) MHC stabilization assay; 
RMA-S cells were incubated overnight with peptide as indicated. Cell surface expression 
of H2-Kb was determined by flow cytometry. Reported values are relative to the H2-Kb 
median fluorescence intensity (MFI) observed with 10 uM OVA peptide.  mCMV, a non-
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Kb-restricted peptide, was used as a negative control. N=3, error bars indicate SEM. (D) 
CD8+ T cells were isolated from the spleens of 2C TCR (SIY-reactive) transgenic mice 
and stained with 1 ug of cognate KbSIY-Ig, cross-reactive KbSVY-Ig, or irrelevant 
KbOVA-Ig. (E) Competitive off-rate binding assay of 2C CD8+ T cells with KbSIY or 
KbSVY peptide MHC dimer over time by the addition of 1B2 TCR binding antibody.  
Cells were gated on CD8+. Cells were stained with KbOVA as negative control or 
experimental pMHC to gate on antigen specific cells over time. This competitive binding 
assay was performed twice, with similar Koff rates determined each time. 
 
To characterize the biophysical interaction of the antigens, we compared their ability to 
stabilize the MHC Kb complex. Both SVY and SIY peptides stabilized the H2-Kb MHC 
molecule to a similar extent, with half-maximal stabilization seen at approximately 100 nM 
(Figure 10.1, c) indicating that SIY and SVY bind H-2 Kb MHC with equal affinity. Using T 
cells from the 2C transgenic mouse, which recognize the KbSIY peptide MHC (pMHC) 
complex, the cross-reactive SVY antigen and the cognate SIY peptides stimulated 2C cytotoxic 
lymphocytes (CTLs) to a similar extent as measured by proliferation ability (data not shown).  
However, differences were seen in the overall binding affinity of the pMHC complexes to 2C 
CTL. Off-rate assays revealed that the H2-Kb SVY complex (KbSVY) has a 4-fold faster koff 
rate and overall lower affinity for the 2C T cells than does KbSIY (Figure 10.1, d). This was also 
seen functionally, as lower frequency of cytokine producing cells were seen over a wide range of 
peptide concentrations in response to SVY and SIY peptide-based stimulations (Figure 10.1, f). 
Thus, it appears that, with similar peptide stability in the MHC molecule, the peptide 
configuration in the MHC complex may be different due to the single amino acid change, thus 




10.2.2 Modeling the Interaction Between KbSVY and KbSIY with the 2C TCR 
To better understand potential cross-reactivity at the TCR level, we investigated the 
change in Kb-peptide-TCR binding for the Val to Ile mutation at position 2 in the epitope 
sequence using molecular dynamics (MD) simulation. Figure 2a shows the constructed three-
way binding complex HLA-epitope-TCR, using the published individual X-ray structures of the 
Kb-epitope and TCR99,100 (see more details in methods). Although the two epitope sequences 
differ only in the second position, the root-mean square deviations (RMSD) per residue 
calculated between the highest populated binding pose of each epitope shows that Tyr3 (4.6 Å), 
Arg4 (3.6 Å), and Leu8 (4.3 Å) deviate more than the mutated residue (Ile2/Val2) (2.9 Å) (Table 
1). The overlapping binding poses of KbSIY and KbSVY show that the side chains of the three 
residues with larger RMSDs deviate between the two epitopes. While the binding poses of the 
two epitopes differ from each other, the binding poses from the same epitope are generally 
consistent among the top five populated clusters, which account for over 98 % of the MD 
trajectories. Through conducting a contact analysis, we found that the contacts at the interface 
between the peptide epitope, Kb, and TCR in the three-way complex vary between epitopes due 
to conformational changes. The frequencies of either Kb or TCR atoms, making close contact 
(less than 6 Å) with the epitopes in the MD trajectories, are presented on the surfaces of Kb and 
TCR. The difference in SIY and SVY contact frequency (Figure 10.2, b) shows the contact 
frequency on both the Kb and TCR surfaces. The contact frequency difference is greater than 80 
% at several regions on the TCR-epitope interface, specifically where TCR atoms contact Tyr3, 
Arg4, and Leu8 of the epitope. These data are consistent with the RMSD analysis, shown in 
Table S1, indicating that the structures of the two epitopes deviate the most at these residues 
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(Figure 10.2, c). Meanwhile, the contact profile at the Kb-epitope interface is more similar 
between epitopes, without the large differences observed at the TCR-epitope interface, indicating 
the altered peptide configuration is mainly on the TCR side.  
We next computed the binding affinity for each of two intermediate steps in the 
formation of the ternary complex, where each epitope is loaded onto the Kb protein, and then the 
Kb-epitope binary complex binds to TCR binds, using the free energy perturbation (FEP) 
method. We found a change in binding affinity (SVY → SIY) of 0.09 ± 0.36 and –1.2 ± 0.2 
kcal/mol for the epitope loaded into Kb, and the subsequent binding to the TCR, respectively 
(Figure 10.2, d). The FEP calculation results indicate that the binding affinity of the SVY 
binding to H2-Kb MHC is similar to that of the SIY binding, however the binding affinity the 
KbSVY complex to TCR is somewhat weaker than KbSIY (about 2KT, or equivalent to ~7.6 
fold difference in the binding equilibrium constant at room temperature). These results are in 
excellent agreement with the biophysical and functional data shown in Figure 10.1 c-e, 
indicating that epitopes indeed have similar binding affinity for Kb, but KbSVY has somewhat 
weaker interactions with the 2C TCR than KbSIY due to the altered peptide configuration. Thus, 
the processing and presentation of EBP from B. breve leads to a SIY cross-reactive response, and 
in fact the SVY antigen can load nicely onto the MHC molecule. However, the amino acid 
substitution alters TCR recognition creating a slightly lower biophysical binding of 2C TCR to p-






Figure 10.2 Modeling highlights differences in SIY and SVY binding to MHC and 
TCR 
(A) Structure of the H2-Kb/epitope/2C TCR complex. The α and β chains of 2C 
TCR and H2-Kb are represented by ribbon models in yellow, blue, red, and 
orange, respectively, and are transparent at the epitope interface. The epitope in 
the box at the center with a dotted line, is represented by a stick model. (B) The 
difference in contact frequency between the SIY and the SVY epitopes on the 2C 
TCR-epitope (left) and the Kb-epitope (right) interfaces. The SIY and the SVY 
epitopes are colored in red and blue, respectively. The surfaces of TCR and Kb 
proteins are colored from blue to red, as the difference of the contact frequency is 
changed from -100 % (SVY) to 100 % (SIY). The red color indicates that protein 
atoms contact the SIY epitope more often than the SVY epitope, while the blue 
color does for the opposite. (C) A zoomed-in image of the binding poses of the 
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SIY (red) and the SVY (blue) epitopes, which are interfaced with H2-Kb and 2C 
TCR on the top and the bottom sides of the figure. The structure of each epitope is 
taken from the frame at the center of the most populated cluster in the MD 
trajectory. Ile2 of the SIY epitope and Val2 of the SVY epitope are colored in 
yellow and green, respectively. The α and β chains of 2C TCR and the α chain of 
H2-Kb are represented by ribbon models in yellow, blue, and red, respectively. 
(D) The relative free energies for the binding of the epitope to Kb (∆∆𝐺𝐾𝑏+𝑒𝑝𝑖), 
and the binding of TCR to the Kb-epitope complex (∆∆𝐺𝐾𝑏/𝑒𝑝𝑖+𝑇𝐶𝑅), between the 






sequence Ser1 Ile2/Val2 Tyr3 Arg4 Tyr5 Tyr6 Gly7 Leu8 
RMSD (Å) 2.45 2.94 4.56 3.63 2.18 1.56 2.24 4.32 
Table 1 The RMSD per residue between the SIY and the SVY epitopes. 
The protein structures were taken from the frame at the center of the highest populated 
clusters in the MD trajectories. The alpha carbons of H2-Kb and 2C TCR were aligned 
between two structures, then the RMSD was calculated for each residue between the SIY 




10.2.3 KbSIY and KbSVY specific T cell populations are cross-reactive 
To study cross-reactivity in endogenous, heterogeneous T cells populations, we analyzed 
SVY- and SIY specific T cells from naïve C57BL/6 mice.  CD8+ T cells from C57BL/6 mice 
were enriched and stimulated with KbSIY or KbSVY based artificial antigen presenting cells 
(aAPC). The resultant day 7 cultures represent a heterogeneous mix of CD8+ T cells specific for 
each individual antigen, as previously described 4 (Figure 10.3, a). Expansion with KbSIY 
aAPCs led to approximately 50.4% KbSIY specific T cells as seen by cognate KbSIY dimer 
staining (Figure 10.3, b, top row, left-hand panel). These were cross-reactive with KbSVY dimer 
which had a similar 49.8% staining and an average expansion frequency of 36.4% (Figure 10.3, 
b, top row, middle panel). MFIs of the antigen reactive populations were 685 for the cognate 
KbSIY dimer and 549 (i.e.: ~20% lower) for the cross-reactive response to KbSVY pMHC 
(Figure 10.3, b, top row). Background noncognate staining was less than 1%. Similarly, 
expansion of T cells with KbSVY aAPCs led to a cognate KbSVY bound T cell population of 
58.1% and a cross-reactive KbSIY bound population of 54.4% of CD8+ T cells with similar 
MFIs and an average expansion frequency on of 31.7% (Figure 10.3, b, lower row). 
Antigen-specific T cells were stained with varying concentrations of KbIg molecules to 
determine the IC50 of the expanded T cells for each peptide-MHC complex and overall T cell 
avidity (Figure 10.3, c). Similar to the findings from the 2C transgenic T cells, KbSIY expanded 
T cells had a higher IC50 (0.1ug) for KbSVY compared to KbSIY(0.01 ug) (Figure 10.3, c, top 
panel).  Differences in overall TCR affinity were also seen functionally as KbSIY expanded T 
cells exhibited a lower trend of cytokine production for the cross-reacting KbSVY antigen re-
stimulation (15% IL-2) than for the cognate SIY pulsed RMA-S cells (30% IL-2) but was not 
significantly different (data not shown). 
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Interestingly, T cells expanded with KbSVY based-aAPCs had equal affinity (0.1 ug) for 
both KbSVY and KbSIY pMHC-Ig complexes (Figure 10.3, c, lower panel) and KbSVY 
expanded T cells produced similar amounts of cytokines in response to both SIY and SVY 
stimulations (data not shown). Cross-reactivity was also tested by analyzing the ability of SVY-
expanded cells to recognize naturally processed KbSIY antigen on B16.SIY murine melanoma 
cells.  Recognition of the naturally processed tumor antigen SIY was seen by cytokine release 
(Figure 10.3, d). Therefore, heterogeneous KbSVY-specific T cells had equal affinity for both 
SIY and SVY and recognize SIY-expressing tumor cells. These data highlight the differences in 
T cell populations expanded by SIY or SVY antigens which result in subtle differences in the 
cross-reactive T cell responses. Together, this demonstrates the overall cross-reactivity of 






Figure 10.3 KbSVY and KbSIY specific T cells are cross-reactive. 
(A) Schematic for isolation, expansion, and staining of antigen specific T cells from 
mouse splenocytes.  Nanoparticles tethered to both peptide-Kb complexes and agonistic 
anti-CD28 antibodies were used as artificial antigen presenting cells to enrich and expand 
antigen-specific T cells.  Expanded T cells were then stained for SIY or SVY epitope 
reactivity. (B) Representative flow cytometry results of KbSIY and KbSVY staining of 
antigen-specific CD8+ T cells enriched from Jackson C57BL/6 mouse splenocytes and 
expanded for seven days. Cells were gated on live, CD8+ cells. (C) Jackson C57BL/6 
mouse splenocytes were isolate and expanded as in in A. KbSIY stimulations top and 
KbSVY stimulations below. On day seven, CD8+ T cells were harvested and stained with 
a titration of pMHC-Ig as indicated and analyzed by flow cytometry.  Results are reported 
as percent peptide-MHC positivity relative to that observed at 10 ug pMHC. KbSIY 
stimulations have a difference in cognate (red) and cross-reactive (black) binding with a 
p-value = 0.016 by 2 way ANOVA Bonferroni post hoc test for multiple comparisons.  
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KbSVY stimulations shows no difference. p = 0.016 N=3 for each antigen expansion. 
Error bars indicate SEM. (D) KbSVY-reactive T cells were isolated from Jackson 
C57BL/6 mouse splenocytes and expanded for seven days as in A. T cells were then 
stimulated with B16.SIY or parental B16.F10 tumor cells and measured for cytokine 
response by intracellular cytokine staining. N=3, p=0.0038 by 2-way ANOVA for 
B16.SIY and B16.F10 response. Error bars indicate SEM. 
 
 
10.2.4 Bifidobacterium colonization enhances SVY-specific T cell expansion. 
Previously commensal Bifidobacterium was shown to promotes antitumor immunity and 
the bacterium associated with anti-tumor response was most similar to B. breve, B. longum, and 
B. adolescentis (99% identity)10. Based on the sequence homology with the cross-reactive 
antigen between B16SIY and B. breve (Figure 10.1, a), we focused our studies on the SVY 
antigen and examined the presence or absence of Bifidobacterium in mice obtained from Jackson 
labs or mice obtained from Taconic, lacking all Bifidobacterium species10 (data not shown). 
KbSVY induced more antigen-specific T cells with a higher average MFI from Jackson than 
Taconic mice (Figure 10.4, a). On average we were only able to expand approximately 8% SVY-
specific T cells from Taconic mice versus 22% from Jackson mice and overall obtained about 4-
fold less SVY-specific T cells from Taconic mice (Figure 10.4, b and c). A lower MFI, 109 
versus 262 was also seen in cells stimulated from Taconic mice.  Similarly, T cells from germ-
free mice showed reduced frequency and total number of SVY-stimulated cells compared to 
Jackson mice (data not shown). 
Overall KbSVY-specific effector T cells from Taconic mice had a lower TCR avidity 
compared to KbSVY-specific T cell populations from Jackson mice (Figure 10.4, d).  However, 
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KbSVY-specific T cells from both populations produced cytokines upon re-stimulation with 
SVY peptide loaded RMA-S cells (data not shown). The impact of Bifidobacterium colonization 
was also seen in analysis of SVY-specific precursory frequency. Jackson mice trended to have 
more KbSVY specific splenocytes compared to Taconic mice (Figure 10.5). Thus B. breve 
exposure increases the expansion capacity of KbSVY-reactive cells leading to higher affinity 





Figure 10.4 SVY antigen in B. breve bacteria stimulates an immunogenic T cell response. 
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(A) CD8+ T cells were isolated and expanded from Jackson and Taconic mouse 
splenocytes with KbSVY aAPCS as in 3A. Cells were harvested and stained for antigen 
specificity on day seven. Representative results from one of 5 independent experiments 
are shown. Gating: live, CD8+ cells. (B) CD8+ T cells were harvested and expanded from 
Jackson and Taconic mouse splenocytes with KbSVY aAPCs and stained for KbSVY 
reactivity. The average percent KbSVY-positivity values from five independent 
experiments are presented. Significance was measured by a one-tailed t test (p>0.005). 
Error bars indicate SEM. (C) Total cells numbers for CD8+ T cells enrichment and 
expansion with KbSVY aAPCs, graph represents 5 independent experiments. 
Significance measured by one-tailed t test (p=0.08) Error bars indicate SEM. (D) 
Antigen-specific CD8+ T cells were isolated and expanded from Jackson and Taconic 
C57BL/6 mouse splenoctyes using KbSVY aAPC particles. On day seven, cells were 
harvested and stained with a titration of KbSVY as indicated and analyzed by flow 
cytometry. Gating: live, CD8+ cells.  Results are reported as percent peptide-MHC 
positivity relative to that observed at 10 ug pMHC. Jackson (blue) and Taconic (red) 
peptide stains were compared at a given concentration via 2-way ANOVA and 
Bonferroni post hoc test for multiple comparisons. N=3 **p<0.0071. (E and F) Taconic 
mice were immunized by intraperitoneal injection of αCD40 on day -8 and subcutaneous 
injection of KbSVY on day -7.  (E) On day 0, control or immunized mice were injected 
intravenously with CFSE-low (antigen loaded) and CFSE-high (no peptide) autologous 
splenocytes mixed at a 1:1 ratio. Spleens were harvested from mice on day 1 and the 
CFSE-low to CFSE-high ratio was analyzed by flow cytometry to determine in vivo 
antigen-specific killing. N=3 mice per group. P<0.0001 by two-tailed unpaired t-test. 
Error bars indicate SEM. (F) Taconic mice were immunized as described in E. The mice 
were sacrificed on day 1 and spleens and draining lymph nodes were harvested and 
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stained for KbSVY specificity. Gating: live, CD8+ cells. p=0.019 by two-tailed upaired t-
test. Error bars indicate SEM. (G) Jackson and Taconic C57BL/6 mice were either co-
housed for seven days or housed with their respective littermates. CD8+ T cells from 
splenocytes were isolated and enriched and expanded with KbSVY aAPCS. Cells were 
harvested and stained for antigen specificity on day seven. Antigen specificity was 
measured by subtracting the non-cognate (negative control) antigen reactivity. N=5 for 
Taconic Only, N = 8/group for co-housed animals. P value = 0.0014 by a one tailed t-test. 
Error bars indicate SEM. (H) Jackson and Taconic C57BL/6 mice were either co-housed 
for seven days or housed with their respective littermates. CD8+ T cells were isolated and 
enriched and expanded with KbOVA aAPCS from splenocytes as a control antigen 
expansion. Cells were harvested and stained for antigen specificity on day seven. Antigen 
specificity was measured by subtracting the non-cognate (negative control) antigen 






Figure 10.5 Jackson mice have a higher precursor frequency of KbSVY cells compared to 
Taconic mice.  
Jackson and Taconic B6 mice splenocytes were isolated and stained with Live/Dead, 
CD8+ T cells, and 1ug of Kb-SVY dimer. Shown is the flow cytometry for 3 individual 
mice, cells gated on Live, CD8+ T cells. 
 
 
10.2.5 SVY antigen is immunogenic and response is transferable via gut 
colonization. 
If SVY is indeed a cross-reactive antigen, one should be able to immunize mice and test 
for cross reactive responses in vivo.  Immunization of Bifidobacterium negative Taconic mice 
with SVY-loaded Kb complexes, as previously described101,  led to approximately 60%  killing 
of SVY target cells in vivo, and a  cross-reactive killing of approximately 50% of SIY-pulsed 
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targets in vivo (Figure 10.4, e).  This was associated with an increased number of KbSVY 
effector T cells, from 0.4% to 0.6% (Figure 10.4, f).  Thus, immunization with SVY elicited an 
in vivo response which was cross-reactive with SIY. 
To investigate if the differences seen between Jackson and Taconic mice were due to 
microbiome, we studied the effect of microbiome transfer on the differences in SVY reactivity. 
Taconic mice co-housed with Jackson mice for a week had a significant increase in KbSVY 
expansion compared to Taconic mice that were not co-housed (Figure 10.4, g). This effect was 
SVY antigen-specific as control KbOVA responses were not influenced by co-housing before T 
cell expansion (Figure 10.4, h).  This antigen specific T cell response based on microbiome 
colonization confirms CD8+ T cells primed in vivo leads to increased expansion capabilities of 
SVY-specific T cells. 
 
10.2.6 Jackson mice have delayed growth of B16.SIY melanoma tumors. 
An implication that differences in the commensal bacteria between Taconic and Jackson 
mice drive a cross-reactive antigen-specific targeting of B16.SIY tumors is that there should be 
differences in tumor growth between the two strains of mice. Indeed B16.SIY tumors grew more 
slowly in Jackson mice than in Taconic mice (Figure 10.6, a) while B16.F10 tumors grew 
identically in the two strains (Figure 10.7). Of note, initially it appeared that tumors grew slightly 
more rapidly in Jackson than Taconic mice, (Figure 10.6, a), but by day 10 tumors in Jackson 
mice were consistently smaller than in Taconic mice.  By day 24, Taconic mice had an average 
tumor size of approximately 146 mm2, whereas Jackson mice were, on average, only 54 mm2 and 
individual spider plots display the slower tumor progression (data not shown). By day 32, all 
Taconic mice succumbed to disease, while 71% of the Jackson mice survived (Figure 10.6, b).  
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We hypothesized that if differences between growth of B16.SIY in Jackson versus 
Taconic mice were driven by antigen-specific recognition of the SIY neoantigen, we should see 
evidence for pressure on SIY antigen in tumors from Jackson mice. Tumors were collected from 
individual mice and analyzed for GFP expression which is encoded by the same vector as SIY in 
the B16.SIY tumors. B16.SIY tumors in Jackson mice had a significant loss of GFP expression, 
from 50% in Taconic mice tumors to 10% in Jackson mice tumors (Figure 10.6, c). 
Tumor infiltrating T cells in B16.SIY tumors show cross-reactivity for KbSIY and 
KbSVY in Jackson mice tumors. Jackson mice TILs were stained for KbSIY specificity or cross-
reactivity for KbSVY and show significant staining over background KbOVA, which is not 
expected to be present in the B16.SIY tumor (Figure 10.6, d). Notably, when TCR sequencing 
was performed on TILs derived from B16.SIY tumors, we found that 22% of TIL clones were 
identical to those detected independently in splenocyte populations sorted and expanded by 
KbSVY.  Overlapping TIL clones consisted of nine of the 198 KbSVY-reactive sequences 
identified by in vitro enrichment and expansion of healthy C57BL/6 mouse splenocytes (P = 
3.42x10-30 for enrichment of SVY-reactive clones in the TIL population by the hypergeometric 
test). Taken together, Jackson mice have a beneficial anti-tumor response that is antigen driven, 
have higher selective pressure against the tumor antigen, and KbSVY cross-reactive T cells can 
be detected in the tumor, all highlighting the beneficial cross-reactive T cell population that is 





Figure 10.6 Jackson mice have an increased anti-tumor response and antigen selective 
pressure on the tumor. 
Jackson C57BL/6 mice (n= 7) and Taconic C57BL/6 mice (n=7) were injected with 
2x106 B16.SIY cells subcutaneously on Day 0. Tumor growth curves show Jackson mice 
have significantly delayed tumor growth as compared to Taconic mice. Significance was 
measured by two-way ANOVA with Bonferroni post-hoc test for multiple comparisons 
(p=0.0455). (B) Additionally, Jackson mice had significantly increased survival 
compared to the Taconic mice. Significance was measured by the log-rank test (Mantel-
Cox tex) ** P=0.0065 n=7 TAC and n=7 JAX (C) Jackson and Taconic C57BL/6 mice 
were injected with 2x106 B16.SIY cells subcutaneously on Day 0. Tumors were 
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harvested at an approximate size of 200-250 mm2 and analyzed by flow cytometry for 
GFP expression. Jackson have a significantly lower GFP expression by unpaired t-test, 
two tailed ** P=0.0030 (n=5 TAC and n=6). (D) Jackson and Taconic C57BL/6 mice 
were injected with 2x106 B16.SIY cells subcutaneously on Day 0. Tumor infiltrating 
lymphocytes were harvested on Day 24 and analyzed by flow cytometry for CD8+ T cell 
specificity, gated on live, CD8+ T cells.  P-value = 0.011, KbSIY; 0.012, KbSVY by 
Unpaired, one-tailed t-test. Error bars indicate SEM. 
 
 
Figure 10.7 Jackson and Taconic mice have a similar tumor growth response to B16-F10. 
Jackson and Taconic B6 mice were injected subcutaneously with B16.F10 (3x10^5 cells) 
in the flank and measured for tumor growth with calipers over time and for overall 
survival. N=5/group for B16.F10 experiment. B16F10 repeated twice with similar results. 
Error bars for SEM. 
 
10.2.7 Bifidobacterium alters the composition of the SVY-responsive TCR 
repertoire 
The impact of B. breve colonization on T cell-specificity was also studied by analyzing 
TCR repertoires expanded by KbSIY or KbSVY from B. breve colonized (Jackson) mice and 
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those lacking B. breve (Taconic). KbSIY and KbSVY-specific T cells from Jackson and Taconic 
mice were stimulated and sorted based on KbSIY or KbSVY staining (Figure 10.8, a). The eight 
T cell populations were analyzed by TCR beta chain sequencing to determine how B. breve 
shapes KbSVY TCR repertoires. 
All four expanded TCR repertoires showed significant overlap when stained with cognate 
or cross-reactive Kb-peptide dimer (Figure 10.8, b). Independent of B. breve colonization, we 
found many overlapping clones when comparing the cognate and cross-reactive sorted 
populations.  By heatmap analysis, the overlapping pairs were in distinct groups with little 
overlap with other repertoires and led to a selection of four distinct TCR populations of SIY and 
SVY cross-reactive clones (Figure 10.8, b). Within Jackson mice T cell repertoires expanded by 
KbSIY, the KbSIY sorted and KbSVY sorted populations shared 47 identical clones comprising 
79.9% of the response (Figure 10.8, b). These populations also shared the same V and J allele 
expression based on heat map analysis (data not shown). Within Jackson mice T cell repertoires 
expanded by KbSVY, the KbSVY sorted and KbSIY sorted populations shared 93 unique clones 
comprising 95.6% of the response (Figure 10.8, b). In Taconic mice, T cell populations expanded 
with KbSIY and sorted on KbSIY or KbSVY had 45 overlapping clones that made up 85.9% of 
the response, while the T cells expanded with KbSVY and sorted on KbSVY or KbSIY had 49 
shared clones comprising 77.1% of the response. Thus, identical T cell clones from cognate and 
cross-reactive staining of expanded cells showed that T cells are cross-reactive for both antigens, 
regardless of the commensal bacteria colonization. 
The relationship between TCR repertoires was also examined using ImmunoMap, a TCR 
homology program we recently developed102. ImmunoMap characterizes the overall homology 
patterns between different T cell repertoires based on homologous complementarity-determining 
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region 3 (CDR3) sequences.  In this fashion multiple repertoires can be overlaid to compare 
homology among various TCRs repertoires (Table 2). The effect of B. breve on TCR repertoire 
composition can be seen when comparing the overlap of SIY or SVY stimulation in Jackson and 
Taconic mice (Figure 10.8, c and d). B. breve negative mice (Taconic) cells stimulated with 
KbSVY reactivity have only 51.1% homology with KbSVY stimulated repertoire from B. breve 
positive (Jackson) mice (Figure 10.8, c, note highlighted boxes and d). In contrast, KbSIY TCR 
repertoire had a significantly overlapping response between Jackson and Taconic stimulations, 
with 71% overlap between both repertoires and highlights that B. breve colonization has a 
greater effect on the composition of the KbSVY-stimulated TCR repertoire than on that of the 
KbSIY-stimulated repertoire (Figure 10.8, d). 
Principal component analysis (PCA) was used to compare the TCR clones based on 
homology of dominant motifs identified from individual repertoires102. While individual 
repertoires all shared similar diversity metrics (Table 2), KbSIY or KbSVY-specific TCR motifs 
from B. breve colonized (Jackson) or non-colonized (Taconic) mice reveal four distinct pairings, 
each driven by supplier and the epitope used for expansion; however, the separation within and 
between pairs was qualitatively greater for Taconic mice than for Jackson mice (Fig. 6e). Taken 
together, TCR repertoire sequencing indicates that the majority of SIY- or SVY-stimulated T cell 
clones are cross-reactive with both epitopes and that B. breve colonization is associated with a 
significantly greater shift in the clonal composition of the SVY-stimulated repertoire than in that 
of the SIY-stimulated repertoire.   
The effect of Bifidobacteria stimulation on the TCR repertoire was also analyzed on T 
cells stimulated in vitro with heat-killed Bifidobacteria. After bacterial stimulation, TCR 
repertoire analysis of the expanded T cells identified 255 unique clones that overlap with Jackson 
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KbSIY or KbSVY stimulated and sorted repertoires by a Hamming distance of 1. The TCR 
clones similar to SIY- or SVY-peptide-reactive TCR repertoires were at a significantly higher 
productive frequency compared to clones present in non-Bifidobacteria stimulated controls (Fig. 
6f). Thus, similar to our in vivo findings, in vitro stimulation with Bifidobacteria expanded a 





Figure 10.8 B. breve colonization shapes the KbSVY TCR repertoire. 
(A) Schematic setup of TCR Repertoire Analysis. CD8+ T cells from Jackson and 
Taconic mice were stimulated with KbSIY or KbSIY aAPCs. On day seven, cells from 
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each stimulation were stained and sorted by antigen reactivity (KbSIY or KbSVY) and 
processed for TCR beta chain deep sequencing. (B) Exact TCR clone overlap between all 
repertoires. Numbers indicate the number of unique overlapping clones between two TCR 
repertoires and the color scale indicates the percent contribution of the overlapping 
sequences to the total combined repertoire for each pair. (C) TCR clone overlap between 
all repertoires based on TCR homology using ImmunoMap algorithm. Numbers indicate 
the number of homologous clusters shared between two TCR repertoires and the color 
scale indicates the percent contribution of shared clusters to the total combined repertoire 
for each pair. (D) Overlap between Jackson and Taconic mice of T cell repertoires 
stimulated by SIY or SVY based on the frequency of homologous TCR clones and 
overlap between SIY and SVY stimulations for Jackson or Taconic mice groups. Data 
included the cognate and cross-reactive sorted populations, as indicated by the black 
boxes in C.  P=0.0016 by two-tailed t-test. Error bars indicate SEM. (E) PCA of 
homology-based TCR clusters. TCR repertoires were analyzed by CDR3 sequence 
homology and separated into dominant motifs.  (F) TCR beta chain deep sequencing was 
performed on Jackson mouse splenocytes incubated with or without heat-killed 
Bifidobacterium. TCR clones with a Hamming Distance of 1 were defined as homologous 
to clones from aAPC expanded KbSIY or KbSVY-specific T cells. Productive frequency 
of these homologous clones from Bifidobacterium stimulated and unstimulated cells are 






Table 2 Summary of TCR clustering of cross-reactive populations by homology. 
TCR clusters analyzed based on homology ImmunoMAP algorithm. Each repertoire is 
described by Shannon Entropy and TCR Diversity Score (based on ImmunoMap algorithm), 




10.2.8 KbSVY reactive T cells inhibit growth of established SIY-expressing tumors 
in vivo. 
One critical question is whether KbSVY-reactive T cells cross-react with the SIY epitope 
in vivo and mediate an effective anti-tumor response. This was studied using KbSVY effector T 
cells from B. breve positive mice (Jackson) for adoptive cellular therapy (ACT). Effector T cell 
populations were generated in vitro and adoptively transferred into B16.SIY tumor bearing mice. 
KbSVY expanded T cells inhibited B16.SIY tumor growth and extended survival in tumor 
bearing mice. By day 22, untreated mice had an average tumor size of approximately 89.87 mm2, 
whereas SVY ACT-treated mice were, on average, only 22.37 mm2 (Fig. 7a, S14a). When we 
analyzed survival data, 60% of KbSVY ACT treated mice survived past 41 days while no control 
mice survived that long (Fig. 7a).  
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ACT-treated mice which eventually developed resistant tumors, were analyzed for 
antigen loss. Tumors were isolated at approximately 135 mm2 and measured for GFP intensity as 
a marker of SIY expression103. The resistant tumors had a decrease in GFP expression compared 
to tumors isolated from a non-treated mouse (Fig. 7b) demonstrating that KbSVY specific cells 
placed selective pressure on B16.SIY tumors resulting in loss of antigen expression. As 
expected, KbSIY-expanded T cells also delayed tumor progression in tumor bearing mice and 
extended survival (Fig. 7c), showing that the repertoire present in KbSIY specific T cells also 
has anti-tumor activity. Thus polyclonal, cross-reactive T cell populations expanded with 
KbSVY decreased tumor growth and increased survival, demonstrating the potential benefits of 





Figure 10.9 Commensal bacteria epitope cross-reactivity mediates an anti-tumor 
response. 
(A) Jackson C57BL/6 mice (n= 5 SVY adoptive cell therapy [ACT], n = 4 No 
Treatment) were injected with 2x106 B16.SIY cells subcutaneously on Day 0. 
CD8+ T cells were harvested from spleens of independent Jackson mice and 
stimulated with KbSVY/anti-CD28 nanoparticles. 1.3x105 of the resultant 
KbSVY-specific CD8+ T cells were injected intravenously into the tumor-bearing 
mice on day 8. Tumor growth curves show SVY ACT treatment significantly 
delayed tumor growth as compared to no treatment.  Significance was measured 
by two-way ANOVA with Bonferroni posthoc test for multiple comparisons 
(p<0.05).  Additionally, KbSVY ACT significantly increased survival compared 
to the no treatment group. Significance was measured by the log-rank test (p = 
0.0015, n= 4 no treatment and n=5 SVY ACT). (B) Jackson C57BL/6 mice were 
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injected with 2x106 B16.SIY cells subcutaneously on Day 0 and treated on day 8 
with 1.3x105 KbSVY-specific CD8+ T cells via intravenous injection. Tumors 
were harvested on day 24 and analyzed by flow cytometry for GFP expression. 
Orange and blue indicate SVY T cell-treated mice and red indicates untreated 
mice. (C). Jackson C57BL/6 mice (n= 3 SIY ACT, n = 3 No Treatment) were 
injected with 2x106 B16.SIY cells subcutaneously on Day 0. CD8+ T cells were 
harvested from spleens of independent Jackson mice and stimulated with 
KbSIY/anti-CD28 nanoparticles.  1.3x105 of the resultant SIY-reactive T cells 
were injected intravenously into tumor-bearing mice on day 8. Tumor growth 
curves show SIY ACT treatment significantly delayed tumor growth as compared 
to no treatment. Significance was measured by two-way ANOVA with the 
Bonferroni posthoc test for multiple comparison  (p<0.05). ACT also significantly 




Understanding the role of antigen mimicry leading to T cell-mediated anti-tumor responses 
is essential in understanding how microbiota can lead to anti-tumor effects. B. breve contains a 
peptide with homology to the SIY epitope, which influences anti-B16.SIY melanoma specific 
responses. Use of B. breve as a source of homologous antigen does not limit the possibility of 
other sources of antigen, although throughout the paper the B. breve antigen sequence shows 
robust cross-reactivity and ability to induce the anti-tumor T cell response both in vitro and in 
vivo. Looking closely, the isoleucine substitution to valine at the second position, did not affect 
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peptide-MHC binding, however the substitution appears to shift the orientation of more distant 
amino acids in the binding pocket, leading to altered TCR recognition. While differences in 
binding with the 2C transgenic TCR illustrated that an individual TCR can display somewhat 
lower affinity for KbSVY than KbSIY, endogenous murine polyclonal SIY and SVY T cell 
responses exhibit striking cross-reactivity.  On a closer examination, TCR beta sequencing 
reveals the exact same clones can bind to both the SIY and SVY antigens after a single 
stimulation. The endogenous KbSIY response is cross-reactive and recognizes both antigens, 
SIY and SVY, albeit with a lower affinity and less robust functional response to the SVY 
antigen. In contrast, KbSVY reactive T cells recognize both peptide antigens with similar affinity 
as well as functional ability, as assessed by their ability to release cytokines in response to tumor 
cells. This difference in cross-reactivity relative to the initial T cell stimulation suggests that 
C57Bl/6 mice possess a heterogeneous SIY/SVY T cell population that can be stimulated by B. 
breve and the polyclonal population contains a range of affinities for SIY and SVY based on 
ability to bind to the slightly altered amino acid orientation in the MHC pocket. 
One of the most interesting findings is that the gut microbiota primes an SVY reactive T 
cell response. While the mechanism of T cell activation and selection by components of the gut 
microbiota is not understood, analysis of mice with and without Bifidobacterium  indicates that 
in vivo priming occurs and boosts the ability to expand SVY-reactive T cells. The SVY antigen 
is immunogenic and can induce an effector T cells that are cross-reactive in vivo with the SIY 
antigen. In addition, the antigen specific T cell response is transferable as demonstrated by co-
housing experiments.  Comparing the TCR repertoires between colonized and non-colonized 
animals revealed SVY-reactive T cells that express TCRs with little or no overlap between the B. 
breve-naïve (Taconic), and B. breve experienced (Jackson) mouse repertoires. An altered SVY-
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expandable TCR repertoire developed in the colonized mice, while the SIY-expandable 
populations showed significantly greater homology between Taconic and Jackson mice. The 
SVY-stimulated TCR repertoires from B. breve-colonized (Jackson) mice contained homologous 
TCR clones that are shared with the Jackson KbSIY stimulation.  These findings suggest that 
differences in B16.SIY, B16.F10 tumor growth between Taconic and Jackson mice may be 
driven in part by a cross-reactive, SVY-primed subset of the TCR repertoire.  In addition, 
stimulating T cells directly with B. breve expands T cell clones that are similar to the Jackson 
KbSIY or KbSVY T cell populations.  These data highlight how commensal bacterial antigens 
may affect the host immune repertoire landscape through antigen mimicry.  An important 
characteristic of the SVY-reactive T cells was their ability to kill SIY expressing tumors in vivo. 
Treatment of B16.SIY tumor bearing animals with adoptively transferred KbSVY-reactive T 
cells showed cross-reactive anti-tumor activity of an endogenous, polyclonal commensal-bacteria 
antigen-stimulated T cell population.  
Importantly, our study illustrates the potential of antigen-mimicry from gut microbes to 
influence T cell immunity, and how this can generate a cross-reactive anti-tumor response. 
Current work identifying beneficial bacteria from responders to immunotherapy as well the 
benefits of fecal transplant in patients has yet to isolate a clear mechanism of action of beneficial 
commensal bacteria; antigen mimicry may play a role in patient responses. Our work has 
confirmed that antigen homology between B. breve SVY and murine melanoma SIY antigen 
stimulates cross-reactive T cells. Furthermore, the addition of B. breve in the microbiome can 
boost the KbSVY T cell population and the new KbSVY response can target and slow tumor 
progression. CD8+ T cell populations driven by commensal bacteria stimulation have shown 
functional responses42,45,49,57, but by identifying the antigen presenting cells responsible and their 
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function will let us further understand the mechanism of effector CD8+ responses produced at 
the gut-immune interface. To translate commensal bacteria homology to tumor antigens in 
patient responses further work needs to be completed, yet the overall diversity of the microbiome 
has been linked to positive respones in patients, potentially with a larger array of antigens 
available to stimulate the T cell response49,50,104.With this mechanism in mind, we believe that a 
rigorous, pan-species genomic analysis of commensal organisms would aid a more precise 
understanding of the effects of microbiota on anti-tumor immunotherapy. Comparing the 
potential neo-antigen T cell responses to the homologous sequences found in patients 
microbiome can provide an effective way to isolate unique T cell populations that can be 
stimulated by both gut microbes and tumor cells and to generate robust antitumor T cell 
responses and use those neo-antigen targets for immunotherapy or identify patients whose 
mutational landscape might better responds to immunotherapy.  
 
10.4 Conclusion 
In conclusion, we have created a proof of concept approach to further understand the role 
of antigen mimicry in the microbiome leading to cross-reactive T cell response and colonization 
can boost the T cell response (Figure 10.10). We have demonstrated the cross-reactivity that can 
occur between the KbSIY and KbSVY antigens. In a system of distinct housing facilities, 
Taconic mice had a lower KbSVY T cell responses, suggesting an in vivo T cell stimulation 
occurring at the gut/immune system interface.  Though we have studied this model of gut 
microbiome cross-reactivity with microbiome changes, our model can be studied in detail with 
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B. breve direct feeding and look closer at the ability to induce a CD8+ T cell response from 
commensal bacteria colonization.  
I hope to continue my work with Panam by comparing the phenotype of CD8+ T cells 
immunize in the classic fashion or via gut colonization with commensal bacteria housing a tumor 
cross-reactive antigen. By creating a model of B. breve SVY+/-, we will confirm the ability of B. 
breve to rescue the KbSVY expansion defect in Taconic housed B6 mice or in germ-free 
animals. With confirmed colonization we can compare the quality of the KbSVY T cell response 
compared to a peripheral immunization model to detect effector function and TCR repertoire 
changes. Also of interest, is to identify the method of cross-presentation of the SVY antigen 
during gut colonization: to identify the responsible antigen presenting cells and elucidate the 
mechanism of CD8+ effector T cells from the commensal microbiome without gut dysbiosis. 
Our work has only just started to understand the mechanism of antigen mimicry from the gut to 
effect the anti-tumor immune response. To understand the clinical application for this 
mechanism, identifying mutations from patients’ tumors and comparing them to commensal 
bacteria will start the process to see if those patients had positive outcomes to CPB 
immunotherapy.  
In terms of translating the work we have completed toward understanding patient 
responses in the context of the microbiome and immunotherapy, the work we have conducted is 
critical in showing the direct effect the microbiome can have on developing an functional T cell 
response. Multiples groups are studying the composition of the microbiome in responders and 
non-responder patients and although certain bacteria diverge for patients in a given study; there 
is limited consistency between studies, which does not suggest a common general activator of 
immune response. Some have argued it is not a particular bacteria but the overall diversity of the 
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microbiome that is the key biomarker to distinguish responder patients105. In terms of the 
mechanism, the microbiome is suggested to boost the maturation and activation potential of 
dendritic cells, although how the activation antigen presenting cells traffic directly to the tumor 
micro-environment is not well supported. To translate this work to patients, by comparing the 
neo-antigen responses and ranking based on homology compared to clinical outcome to vaccine 
or checkpoint blockade may better explain the frequency of antigen mimicry on T cell responses. 
Alternatively, using a Bifidobacterium based gut platform with expressed tumor antigens 
expressed in the genome, a tumor antigen T cell response may be induced via gut T cell 
activation.  Either as a predictor of patient response or use as a potential therapy directly, the 
hypothesis of mutational landscape responses shaped by the microbiome-immune response is an 





Figure 10.10 Antigen mimicry on commensal bacteria leads to tumor clearance.  
A schematic representation of the cross-reactive T cell population resulting from antigen 
mimicry between commensal bacteria and tumor antigen. Commensal bacteria antigen is 
taken up at the gut by antigen presenting cells to stimulate T cells which traffic to the 
tumor microenvironment and can detect and lyse tumor cells.  
 
 
10.5 Experimental Methods  
Mice: C57BL/6 were purchased from Jackson Laboratories (Bar Harbor, ME, USA) and Taconic 
Farms. 2C TCR transgenic mice were kept as heterozygotes by breeding on a C57/BL6 
background. All mice used were 8-12 weeks of age and were maintained according to Johns 
Hopkins University’s Institutional Review Board. 
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Peptide Stabilization Assay: RMA-S cells were left at 25°C overnight and pulsed for 2 hours 
with titration of peptide and put at 37°C for 2 hours to degrade unstable MHC molecules. Cells 
were stained with anti-Kb clone M1/42 and analyzed by flow for MHC expression.  
2C Functional Analysis: 2C effector T cells, stimulated from splenocytes with peptide for 5 days, 
were harvested and re-stimulated with RMA-S cells peptide pulsed overnight. T cells and   
RMA-S cells were incubated at a 1:1 ratio along with Golgi-stop and Golgi-block and CD107a 
(FITC,1D4B). After 6 hours, cells were stained with viability stain (ThermoFisher, L23101)  and 
anti-CD8+a (PerCp, 53 6.7). Cells were fixed and permeabilized (BD, 554714) and stained for 
INFg (PE, XMG1.2), TNFa (PECy7, MP6 XT22), and IL-2 (APC, JES6 5H4).  
Competitive binding assay: 2C effectors T cells were stimulated with SIY peptide for five days 
and then stained with fluorescent dimer for one hour. Afterwards, saturating amounts of an 
unconjugated competitor 1B2 antibody was added and TCR-dimer binding was measured by 
flow cytometry over time. 
Bifidobacteria quantification: Fecal samples were collected from mice from Jackson 
Laboratories and Taconic Biosciences.  DNA was isolated using the ZymoBIOMICS DNA/RNA 
miniprep kit (Zymo Research).  Bifidobacteria colonization relative to total eubacteria was 
quantified by multiplexed quantitative real-time PCR analysis of microbial rRNA genes.  The 
following primers and Taqman probe were used for detection of Bifidobacteria rRNA: 5’-
cgggtgagtaatgcgtgacc-3’, 5’-tgataggacgcgacccca-3’, and 5’-6FAM-ctcctggaaacgggtg-QSY-3’106.  
The following primers and Taqman probe were used for detection of total eubacteria rRNA: 5’-
tcctacgggaggcagcagt-3’, 5’-ggactaccagggtatctaatcctgtt-3’, and 5’-JUN-cgtattaccgcggctgctggcac-
QSY-3’107.   
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Bifidobacteria stimulation of murine T cells: Splenocytes and mesenteric lymph node cells were 
isolated from C57Bl/6 mice obtained from Jackson Laboratories.  Cells were suspended in media 
(RPMI containing 10% heat-inactivated FBS, 50 uM beta mercaptoethanol, 1 unit/mL penicillin, 
1ug/mL streptomycin, and 20 IU/mL recombinant murine IL-2 [R&D Systems]) at 2x106 viable 
cells per mL.  4x106 cells were seeded per well in a 24-well plate.  Bifidobacterium and 
Lactobacillus probiotic capsules were obtained from SeekingHealth®.  One capsule was 
resuspended in 10 mL of PBS and heated at 57 ˚C for one hour.  Splenocytes were stimulated 
with 160 uL of the heat killed resuspended bacteria (approximately 50-u100 bacterial cfu per 
splenocyte) or left unstimulated. Cultures were maintained at 37 ˚C at 5% CO2 for eleven days.  
Fresh media and IL-2 were added every other day.  Cultures were then stained with APC-Cy7-
anti-CD8a Clone 53-6.7 (Biolegend), DAPI, and either PE-Kb-SIY dimer or a control PE-Kb 
dimer.  Cell were analyzed on an LSRII flow cytometer (BD).  Cells were gated on live cells and 
CD8+ T cells. Antigen specific frequency was calculated by subtracting the non-cognate 
background staining. DNA was extracted from 4x105 remaining cells using the DNAeasy Blood 
and Tissue kit (Qiagen).  Extracted DNA was submitted to Adaptive Biotechnologies for survey-
level TCR beta chain sequencing. 
Preparation of MHC-Ig Dimers and Nanoparticles: Soluble MHC-Ig dimers Kb-Ig was prepared 
in house and loaded with SIY or SVY peptides as described108.  αCD28 antibody was purchased 
from Biolegend (37.51; Biolegend San Diego, CA, USA). KbSIY particles were manufactured in 
house and by Miltentyi. Soluble MHC-Ig dimer and Nano-aAPC αCD28 antibody were 
conjugated to 100nm paramagnetic iron oxide particles by Milenyi. In house particles were 
manufactured by directly conjugating KbSIY-Ig or KbSVY-Ig and αCD28 to amine coated 
labeled 80-100 nm super paramagnetic iron-oxide particles (SPIONS) purchased from Micromod 
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(Rostock, Germany) and functionalized according to manufacturer’s recommendations. Briefly, 
amines on particles reacted with Sulfo SMCC (Proteochem, Hurricane, UT) and then 
magnetically washed. Soluble peptide-MHC-Ig and αCD28 were modified with 2 iminothiolane  
(Traut’s reagent) purchased from Sigma Aldrich (St. Louis, MO). Excess 2 iminothiolane was 
washed away from protein solution by using a Vivaspin 20 50kDa MWCO concentrator (GE  
Healthcare, Little Chalfont, United Kingdom). Peptide-MHC-Ig and αCD28 are mixed to 1:1 
ratio and added to washed particles and mixed overnight at 25°C. Particles are then washed and 
stored at 4°C. Nano-aAPC were stored at a concentration of 5 × 1012 particles/mL. 
T cell E&E stimulations and Cross-reactivity: C57BL/6 mice spleens and lymph nodes were 
harvested, and isolated with no touch CD8 kits (Miltenyi) as manufacturer’s instructions. CD8+ T 
cells were incubated with nanoparticles at 10ul of particles per 107 CD8+ T cells at 4° C for 1 hr 
and cells are washed over MS Miltenyi column. Then, the positive fraction was eluted and plated 
at 2.5x105 cells/mL for a 7 day stimulation. Isolated fractions were mixed and cultured in 96-well 
round-bottom plates for 7 days in complete RPMI-1640 medium supplemented with 10% human 
autologous serum and 3% T cell growth factor, a cytokine cocktail derived from stimulated 
PBMC as described in the literature4, in a humidified 5% CO2, 37 °C incubator for 1 week. 
Specificity of CTL was monitored on day 7, by FACS analysis following dimeric MHC-Ig 
staining and rat anti mouse CD8a, clone 53-6.7 (Biolegend). The number of antigen-specific 
cells was calculated by multiplying the number of total live cells by the fractions of CD8+ and 
antigen-specific cells; the fraction of antigen-specific cells was calculated after subtracting the 
noncognate MHC staining from cognate MHC staining. Splenic E&E stimulations modified with 
particles added to RBS lyzed splenic cells at 1ul particles/107 cell and after particle elution plated 
in 96 well u bottom plate at 5x105 cells/mL and stimulated for 7 days.  
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T cell cytokine response: After 7 days of culture, T cells were counted using a hemocytometer.  
200,000 T cells were taken per condition and separated into restimulation or no stimulation 
groups. A solution of 1:350 BD GolgiStop Protein Transport Inhibitor (BD Biosciences) and 
1:350 BD GolgiPlug Protein Transport Inhibitor (BD Biosciences) and αCD107a FITC was 
added to the cells in RPMI 1640 medium supplemented with 10% fetal bovine S23 serum. RMA-
S pulsed overnight at 25°C with peptide (cognate/crossreactive/irrelevant) were washed and 
added to cells to be restimulated at a 1:2 ratio. Cells were then allowed to incubate in a cell 
incubator for 6 hours at 37°C. Following the incubation, cells were washed and then stained with 
50 μL of a  1:100 solution of PerCP conjugated rat anti mouse CD8a, clone 53 6.7 (Biolegend) 
and 1:1000  LIVE/DEAD® Fixable Green Dead Cell Stain (ThermoFisher) for 15 minutes at 
4°C. Cells were then washed with PBS and 100 μL of BD Cytofix/Cytoperm Fixation and 
Permeabilization Solution was added to the cells and allowed to sit overnight at 4°C. Following 
the fixation step, 100 μL of 1x BD Perm/Wash Buffer (10x solution diluted to 1x in a solution of 
2% bovine serum albumin in dH2O) was added to the cells and washed. Cells were again washed 
with 200 μL 1x BD Perm/Wash Buffer. Cells were then stained with a solution of 1:100 solution 
of PE conjugated rat anti mouse IFNγ, clone XMG1.2 (BD Pharmingen), APC conjugated rat 
anti mouse IL2, clone JES6 5H4 (BD Pharmingen), and PE Cy7 conjugated rat anti mouse 
TNFα, clone MP6 XT22 (Biolegend) for 1 hour at 4°C. Cells were washed with FACS wash 
buffer and then read on a BD LSR II flow cytometer. Background cytokine staining was 
accounted for by subtracting cytokine positive cells in non-stimulated conditions from the re-
stimulated cells. 
MD simulation setup: Each system consists of a protein complex in one of the following three 
states: 1) the epitope only, 2) the epitope bound to H2-Kb MHC (Kb/epitope binary complex), 
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and 3) 2C TCR bound to the H2-Kb/epitope complex (Kb/epitope/2C TCR ternary complex). 
The epitope sequence of each system was chosen to be either SIYRYYGL (SIY) or 
SVYRYYGL (SVY). The initial coordinates of H2-Kb and 2C TCR were taken from the X-ray 
crystal structure of each (PDB 3P9L99: H2-Kb; PDB 2OI9100: 2C TCR). The initial configuration 
of the epitope was built based on the OVA257-264 epitope (SIINFEKL), which is complexed with 
H2-Kb in the crystal structure. The OVA epitope was mutated to either SIY or SVY epitopes 
using VMD mutator plugin109. The H2-Kb/epitope/2C TCR complex was constructed in the 
following steps: the coordinates of 2C TCR in the crystal structure were adjusted by aligning the 
alpha carbons of H2-Kb and MHC protein between the two crystal structures, then the structures 
of H2-Kb, epitope, and 2C TCR were combined into one system. The protein complex was 
placed in the center of a rectangular box with a periodic boundary condition. The rest of the 
empty space of the box was filled with water molecules using the Gromacs tool solvate110. The 
size of the simulation box for the protein complex in the states 1, 2, and 3 were 60 Å × 60 Å × 60 
Å, 83 Å × 90 Å × 114 Å, and 86 Å × 90 Å × 145 Å, respectively. The length of each side of the 
box was set to be sufficiently large that proteins at the center of the box are separated at least 30 
Å away from their periodic images. The protonation states of His residues of the proteins were 
determined based on an optimal hydrogen bonding conformation, determined by the Gromacs 
tool pdb2gmx. His93 of the α-chain of H2-Kb MHC, and His29 of the β-chain of 2C TCR were 
singly protonated at the Nδ1 atom. His84 of the β-chain of H2-Kb was doubly protonated at the 
Nδ1 and the Nε2 atoms. All other His residues were singly protonated at the Nε2 atom. Standard 
protonation states were chosen for all other residues. Na+ and Cl- ions were added in the solvent 
using the Gromacs tool genion, to neutralize the protein systems, as well as mimicking the 
physiological ionic concentration, 150 mM. The CHARMM36 force field111 was employed for 
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the protein and ions, and TIP3P model112 for waters. The MD simulations were performed with 
Gromacs package version 5.14110. Long-ranged electrostatic interactions were treated with the 
Particle Mesh Ewald (PME) method113. The cut-off distance for both the Lennard-Jones and the 
real space Coulomb interaction was set to be 12 Å. All covalent bonds involving the hydrogen 
atoms of the protein and water molecules are constrained by the LINC algorithm114. Each system 
was minimized at zero temperature for 1000 steps, then equilibrated in NPT ensemble with a 
temperature of 300 K and a pressure of 1 atm for 1 ns. The timestep was set to be 2.0 fs. After 
the total volume of the system was stabilized in NPT ensemble, the system was equilibrated 
again in NVT ensemble at 300 K for 100 ns. Then, the NVT simulation was extended for another 
500 ns for the production run. The temperature and the pressure were controlled by Nose-
Hoover115 and Berendsen116 schemes,. The system coordinates were written every 100 ps during 
the production run, then all MD frames were clustered by the RMSD of the protein complex 
using gromos method117. The RMSD cutoff value of each cluster was set to be 2.5 Å. 
Free energy perturbation (FEP): The FEP calculation was performed to calculate the relative free 
energy changes of the systems in three states, while Val2 of the SIY epitope is mutated to Ile2. 
The hybrid structure and topology of each system were generated by the PMX software118. The 
alchemical transformation from Val2 to Ile2 was governed by the hybrid Hamiltonian H(λ), as a 
function of the coupling parameter λ99. 
 
𝐇(𝜆) = (1 − 𝜆) ∙ 𝐇V + 𝜆 ∙ 𝐇I + 𝐇0                                               (1) 
 
HV and HI are the Hamiltonians for the atoms of Val2 and Ile2, respectively, which undergo the 
alchemical transformation during the simulation, and H0 is the Hamiltonian for the rest of the 
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system, with a fixed topology. 34 λ-windows were generated between λ = 0 and λ = 1, where the 
λ-interval between neighboring windows was fixed to 0.04 between λ = 0.02 and λ = 0.98, and 
gradually decreased from 10-2 to 10-5, as λ approaches to both ends, λ = 0 and λ = 1. To circumvent 
numerical instability caused by insertion or deletion of atoms in the simulation, the soft-core 
potential119 was applied to both the Van der Waals and the electrostatic interactions for the atoms 
in the alchemical domain. The λ value for the electrostatic interaction was fixed to zero at the 
windows between λ = 0 and λ = 0.1, then rescaled linearly to [0, 1] at the windows between λ = 
0.1 and λ = 1, while the λ value for the Van der Waals and the bonded interactions was set to be 
equal to that of the window. At each λ-window, the system was equilibrated for 100 ps, followed 
by the production run for 500 ps. The simulation was carried out sequentially from λ = 0 to λ = 1, 
so that the initial coordinates and velocities of each window were taken from the last MD frame 
of the previous window. The setup for the MD simulation part was the same used in the NPT 
simulation in the earlier section. All other FEP setups were the same used in our previous 
studies120–123 on other MHC-epitope-TCR systems.  
The free energy change (∆𝐺) was calculated using the thermodynamic integration (TI) 
method108,124,125, in the equation as follows100,  






                                                       (2) 
where 〈(𝝏𝑯(λ, 𝐱) 𝝏𝜆⁄ )〉𝜆 is the ensemble average of the derivative of the hybrid potential with 
respect to λ. 𝝏𝑯(λ, 𝐱) 𝝏𝜆⁄  was written every 0.1 ps. ∆𝐺 was calculated for each of three systems 
with different protein complexes as listed above (∆𝐺𝑒𝑝𝑖, ∆𝐺𝐾𝑏/𝑒𝑝𝑖, and ∆𝐺𝐾𝑏/𝑒𝑝𝑖/𝑇𝐶𝑅). Statistical 
error of ∆𝐺 was estimated using the block average method by dividing the trajectory of each 
window into four consecutive blocks. To better sample the conformational change of the protein 
complex, ∆𝐺𝐾𝑏/𝑒𝑝𝑖 and ∆𝐺𝐾𝑏/𝑒𝑝𝑖/𝑇𝐶𝑅 were averaged over five independent runs, started from 
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different initial configurations. Each initial configuration was taken from the frame at the center 
of each of the top five most populated clusters from the MD simulations, as shown in Figure S3. 
∆𝐺 of each individual run was weighted by the population of each cluster. Due to its small 
system size, ∆𝐺𝑒𝑝𝑖 was calculated from a single run. The calculation details are shown in Table 
S2. The relative free energy changes for the two reaction steps during the formation of the 
protein complex, ∆∆𝐺𝐾𝑏+𝑒𝑝𝑖 and ∆∆𝐺𝐾𝑏/𝑒𝑝𝑖+𝑇𝐶𝑅, defined in the main text, were calculated in the 
equations as follows109,110. 
∆∆𝐺𝐾𝑏+𝑒𝑝𝑖 = ∆𝐺𝐾𝑏/𝑒𝑝𝑖 − ∆𝐺𝑒𝑝𝑖               (3)  
(Humphrey et al., 1996)(Humphrey et al., 1996) 
∆∆𝐺𝐾𝑏/𝑒𝑝𝑖+𝑇𝐶𝑅 = ∆𝐺𝑘𝑏/𝑒𝑝𝑖/𝑇𝐶𝑅 − ∆𝐺𝐾𝑏/𝑒𝑝𝑖                                          (4) 
Immunization Assay: Protocol taken from Schutz et. al. Briefly, recipient C57BL/6 mice were 
injected intraperitoneal with 10 µg/mouse of anti‐CD40 mAb (clone 3/23; BioLegend, San 
Diego, CA) and a day later immunized subcutaneously with 250ug indicated of either OVA−Kb‐Ig 
or SVY−Kb‐Ig dimer. 
In Vivo Killing Assay: Target cells for the in vivo cytotoxic assay were obtained from 
splenocytes of naïve C57BL/6 mice, cleaned from erythrocytes by osmotic lysis, washed and 
split into two populations. The control population was pulsed with 1 µM SIY peptide, incubated 
at 37°C for 20 min, and labeled with a high concentration of CFSE (2.5 µM) 
(unlabelled−CFSEhigh cells). The second control target population was pulsed with 1 µM SVY,SIY or 
OVA peptide and was labeled with a low concentration of CFSE (0.25 µM) (target−CFSElow cells) 
(Invitrogen, Eugene, OR). The two populations were mixed together at 1:1 ratio and 
intravenously injected in pep−MHC dimer immunized C57BL/6 mice (10 × 106/population/mouse) 
7 days after immunization with KbSVY-Ig dimer, KbOVA-Ig dimer, or no immunization control 
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mice. After 18 h the mice were sacrificed and spleen. The cell suspensions obtained from the 
spleen were analyzed by FACS for presence of two differentially CFSE labeled target 
populations. The recovery and percent killing of the various CFSE‐labeled, peptide‐pulsed target 
cells were calculated as follows: % of in vivo killing = 100 − ([(% specific peptide pulsed cells in 
immunized C57BL/6/% unspecific peptide pulsed cells in immunized C57BL/6)/(% specific 
peptide pulsed in naïve C57BL/6/% unspecific peptide pulsed cells in naïve C57BL/6)] × 100). 
In Vivo Tumor Experiments: 8 week old C57BL/6 mice were injected with B16.SIY (2x106 cells) 
or B16.F10 (1x105 cells) in the flank and measure for tumor growth with calipers over timer and 
monitored for survival. 
Co-housing experiment: 8 week old C57BL/6 mice from Taconic and Jackson facilities were co-
housed in fresh cages for 7 days. On day 7, age matched Taconic mice, co-house Taconic mice, 
and co-housed Jackson mice were sacrificed and spleens isolated for CD8+ T cell E&E for 
KbSVY and KbOVA T cell stimulations.  
TCR repertoire analysis: In order to compare repertoires between Jackson and Taconic mice 
with SIY vs. SVY stimulations and their cognate versus non-cognate stains, a custom R script 
was developed to analyze CDR3 data obtained from Adaptive Biotech based on both exact and 
homology overlaps between groups. Only sequences with a productive frequency >0.01% were 
included in the analysis. For exact overlap analysis, CDR3 reads were normalized within 
samples and then compared across all samples. First, the number of unique CDR3s and the 
overall contribution from shared sequences were compared. Next, principal component analysis 
(PCA) was performed and samples were plotted in terms of their top two principal components 
to examine sample clustering behavior in the lower dimensional space. Additionally, a heatmap 
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representation was drawn using row-wise Z scores. Finally, the Jensen Shannon Divergence was 
computed in terms of the Shannon’s entropy of each CDR3 distribution as126: 









(𝐻(𝑃) + 𝐻(𝑄))#(5) 
where the Shannon’s entropy in terms of the frequency of all N unique CDR3s, 𝑝(𝑖) is100: 




For homology overlap analysis, the Immunomap algorithm was used.2 Briefly, pairwise distance 
scores between all unique CDR3s were calculated using a PAM10 substitution matrix, a gap 
opening penalty of 30, and a gap extension penalty of 0, and the Immunomap distance metric 
was calculated. Then average hierarchical clustering was performed and a homology threshold of 
0.35 was used. Finally, dominant motifs were defined as homology clusters with a frequency 
greater than 3%. Homology overlaps were represented in a similar manner as above. 
Tumor ACT: To test the anti-tumor benefits of effector T cell populations B16.SIY bearing mice 
were treated with adoptive cellular therapy (ACT) and monitored for tumor growth and survival. 
Jackson mice were stimulated with KbSVY nanoparticles and transferred into partially ablated 
tumor bearing mice. Jackson C57BL/6 were injected with B16.SIY tumor cell line at 2x106 cells 
subcutaneously per mouse. 7 days after tumor injection mice were partially ablated with 5 cGy to 
create room for adoptively transferred cells. On day 8, day 7 stimulated KbSIY or KbSVY 
specific CD8+ T cells were transferred into tumor bearing animals by retro-orbital injection with 
1.3x105 antigen specific cells/mouse. On day 8 and day 9 mice receive IL-2 30,000 units by 
intraperitoneal injection. Mice were measured 3 times/week for tumor growth and survival and 
tumor volume was reported in mm2. 
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TILs Isolation: Tumor infiltrating lymphocytes were obtained from tumors by manual digestion 
and washing, a density gradient centrifugation (Lympholyte Cell Separation Media, Mouse, 
Cedar Lane), and then tumor cells were counted and used flow cytometry analysis. All cell lines 
underwent testing for mycoplasma contamination. 
Statistics: Information on statistical tests is present in all figure legends. One and two-way 
ANOVA were used when making multiple comparisons. Bonferroni post-tests were performed 
when comparing all groups, and Dunnett’s post-tests were performed when the hypotheses being 
tested involved comparison against a single group. One-tailed and two-tailed t tests were used 
when comparing two groups, as indicated in figure legends. All data sets were assumed to fit a 
normal distribution, and all graphs show mean and error bars represent SEM. All n values are 
present within figure legends.  Mice with outlier tumor size before the beginning of treatment 
were removed from the studies. Randomization was performed by cage in all animal studies. All 





11 Additional Work  
11.1 Contribution to other Schneck Laboratory Projects 
11.1.1 Introduction of Incomplete Projects 
Sprouty2 Project: Sprouty2 (Spry2) was initially identified in the Schneck lab from a 
microarray analysis of proteins upregulated after increasing anti-CD3/anti-CD28 T cell 
stimulation of healthy CD8+ T cells (data not shown). Spry2 is a negative regulator of the Erk 
signaling pathway during TCR T cell signaling. Sprouty-1 had previously been identified as a 
regulator of effector function in CD4+ and CD8+ T cells127. From the work in the Schneck lab, 
Spry2 was identified to be key in regulating polyfunctionality of CD8+ T cells, polyfuctionality 
is the ability for an effector CD8+ T cell to produce multiple cytokines in a single T cell upon 
antigen stimulation128. The loss of polyfunctionality in CD8+ T cells is associated with T cell 
exhaustion, the process of effector T cells to lose expansion, lyses and cytokine function toward 
their antigen of interest which is common in chronic T cell stimulation with poor clearance of 
antigen129. Spry2 was specifically enriched along with PD-1 expression in HIV specific CD8+ T 
cells in HIV+ patients, while the viral influenza response was not impacted in function or 
exhaustion markers128. Below is data collected in both murine and human cancer systems to 
determine if Spry2 is upregulated in exhausted T cells in the setting of tumor immunology. The 
work has not been published but suggests to potentially explain how chronic T cell stimulation in 
the tumor microenvironment could inhibit T cell function through Spry2, but further work would 




Neo-antigen Characterization Project: The neo-antigen T cell compartment has been 
suggested as the potential dominate T cell response responsible for positive outcomes for cancer 
immunotherapy patients17,21. Neo-antigen T cell responses have the potential to be less inhibited 
and maintain higher affinity T cell clones in the repertoire compared to self-tumor antigens8 . We 
wanted to compared the exhaustion phenotype between neo-antigen and self-tumor antigen 
responses in tumors, and determine the exhaustion phenotype profile for both types of antigens. 
Below is data collected using neo-antigens epitopes in B16-F10 murine melanoma12 identified by 
an aAPC T cell stimulation screen, conducted by the Schneck group.  These neo-antigen T cell 
responses were compared to KbTRP2, a self-tumor melanoma response. The work has not been 
published but with future experiments may show the beneficial neo-antigen responses compared 
to self-tumor antigen responses, and/or a difference in T cell exhaustion markers after tumor 
infiltration.  
 
11.2 Spry2 in Tumor Expression  
Spry2 has been identified as a negative feedback regulator of the Erk signaling pathway 
during T cell activation127. From in vitro studies in the lab, Spry2 is upregulated with increasing 
the concentration of plate bound α-CD3 during α-CD3/α-CD28 CD8+ T cell activation in both 
human128 and murine systems (data not shown). With increasing α-CD3 signal, murine CD8+ T 
cells increase proliferation activity, decrease cytokine production ability, and increasing Spry2 
expression (data not shown). Separate from TCR activation strength, a cytokine screening 
revealed TGF-β can increase Spry2 expression during T cell activation (data not shown). To test 
if the inhibitory microenvironment of the tumor will increase Spry2 expression in CD8+ T cells, 
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PMEL CD8+ T cells were adoptively transferred into B16.F10 tumor bearing mice and after 2 
weeks were harvested from spleens and tumors of mice. The PMEL CD8+ T cells recognize the 
Dbgp100 tumor antigen expressed by the melanoma cells, and are marked with Thy1.1 congenic 
marker for identification of transferred cells. Compared to splenic PMEL T cells, PMEL tumor 
infiltrating lymphocytes (TIL) had a higher MFI in Spry2 (Figure 11.1). Within the TILs 
compartment, the PMEL cells had a PD-1 hi and a PD-1 low expression population (data not 
shown) and Spry2 expression was increased in the PD-1 hi population (Figure 11.2). Taken 
together, the data suggests Spry2 is induced in the tumor microenvironment and is co-expressed 





Figure 11.1 Spry2 Expression in TILs. 
PMEL T Cells in Tumor have higher Spry2 expression compared to splenocytes and 
isotype control. B6 mice with B16-F10 subQ tumors were irradiated and transferred with 
PMEL Thy1.1 T cells, APCs, and IL-2 (IP) and collected after 14 days. Second IL-2 
treatement D1 after transfer. (n=3) 
 





























Figure 11.2 Spry2 is Co-expressed with PD-1 Hi TILs 
Spry2 MFI levels compared between PMEL PD-1 Low (PD-1 Low MFI 113) and PD-1 
High (PD-1 High MFI 11793) TILs. B6 mice with B16F10 tumors were irradiated and 
PMEL and aAPCs were transferred into recipient mice for 2 weeks. TILs isolated and 
analyzed by flow cytometry. Cells gated on Live/CD8/Thy1.1 (n=3) 
 
 In an alternative approach, pancreatic ductal adenocarcinoma tissue slides were stained 
by IHC with Spry2 and DAPI to compare Spry2 expression in lymphocytes. Compared to 
healthy adjacent tissue, more lymphocytes surrounding the abnormal ductal tissue had Spry2 
expression. Below is a representative picture of healthy control tissue and abnormal ductal tissue, 
both stained with DAPI and Spry2 (Figure 11.3). Both tissues had lymphocyte infiltration, 
although the abnormal tissue has an increase of lymphocytes, but Spy2 expression is detected 
robustly in the abnormal tissue slide. Lymphocytes were identified by the size of the cell relative 
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to the nuclear size and shape.  With multiple pancreatic patient samples and adjacent healthy 
tissue controls, Spry2+ in the lymphocytes increases 3 fold in abnormal tissue compared to 
healthy tissue (Figure 11.4). Future work to identify the phenotype of the infiltrating 
lymphocytes will confirm if Spy2 is an additional marker of exhaustion in TILs.  
 
 
Figure 11.3 Spry2 IHC in pancreatic cancer tissue. 
Abnormal pancreatic tissue and adjacent normal ductal tissue stained for DAPI and Spry2 





Figure 11.4 Higher Spry2 infiltration in pancreatic cancer. 
Lymphoctye cells in healthy and abnormal compared by Spry2 staining. Compared to 
lymphocyte infiltration in healthy adjacent tissue, abnormal ducts in pancreatic cancer 
have higher Spry2+ lymphocytes. (7 abnormal samples, 3 normal controls). P-value < 
0.05 by unpaired T-test. 
 
11.3 Characterization of Neo-antigens 
Neo-epitope T cell responses have been detected in immunotherapy patients years after 
initial treatment and response17. The Schneck lab has been interested in comparing neo-antigen 
specific T cells to self-tumor specific T cell phenotype after tumor infiltration, to understand the 
therapeutic potential of both T cell subsets. Neo-antigens were identified in B16-F10 murine 
melanoma model12 but the short 9-10 amino acid sequences were not confirmed.  The Scheck lab 
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identified potential neo-antigens epitopes using the NetMHC prediction algorithm and created 
aAPCs to screen B6 CD8+ T cells for stimulation ability in naïve animals (Figure 11.5). The 
Schneck lab screened 18 potential neo-antigens and confirmed 11 neo-antigen responses in naïve 
B6 animals (data not shown).  B6 mice were then injected subcutaneously with B16.F10 
melanoma cells and after 14 days CD8+ T cells from the spleen were harvested and stimulated 
for 2 neo-antigens KbVDW and KbVTF, and compared to KbTRP2 and KbSIY T cell 
stimulations; and naïve animals were harvested and stimulated for naïve expansion ability. 
KbVDW and KbVTF neo-antigen T cells had 4 fold higher expansion ability in tumor-bearing 
compared to naïve animals, while the KbTRP2 response was not changed (Figure 11.6). KbSIY 
was expected to be unchanged between tumor-bearing and naïve animals, since B16-F10 does 
not express the SIY antigen. Future work to characterize neo-antigen and self-tumor antigen 
response will include testing additional neo-antigens and other self-tumor responses to compare 
the expansion ability of the T cells. Furthermore, by looking directly at TILs, neo-antigens and 
self-tumor antigens can be phenotyped for activation and exhaustion markers with and without 





Figure 11.5 Pipeline for Identifying Neo-antigens Epitopes in B16-F10 Model 
A schematic to show the pipeline to screen potential neo-antigen epitope sequences from 
Castle et al. (ref) to identify 9-10 amino acid (aa) long sequences from 27 aa long 
sequence. After potential neo-antigen epitopes are loaded into MHC-Ig molecules, T cell 







Figure 11.6 Tumor selectively stimulates Neo-antigen Specific Response 
B6 mice were injected subquetaneously with B16-F10 tumors and after 14 days, splenic 
T cells were harvested and tumor antigens specificities were compared to naïve T cell 
frequencies. Compared to KbTRP2, the self-tumor antigen, both neo-antigens KbVDW 
and KbVTF increase expansion ability. KbSIY antigen is not expressed by this tumor and 
is expected not to change in with tumor presence.  
  
 
11.4 Conclusion  
Spry2 project: Although the spry2 needs additional experiments, the work we have done so far 
is encouraging toward identifying spry2 as an upregulated marker in lymphocytes that have 
infiltrated and become exhausted in the tumor. Spry2 upregulation in TILs would be a novel 
marker of exhaustion in the tumor, and identify the subset of TILs with limited function based 
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not only on PD-1 signaling, but a separate negative regulator of the Erk signaling pathway. 
Another biomarker of T cell exhaustion could serve has a method to distinguish different levels 
of T cell inhibition and be correlated with response to check-point blockade treatment.  
 
Characterization of neo-antigens: Although many groups have shown benefit in patients by 
targeting the neo-antigen T cell response. Yet only a subset of patients have long term survival 
with checkpoint blockade therapy18. Understanding how self-tumor responses and neo-antigen T 
cell responses react in the tumor and with different immunotherapies may increase the 
predictable patient outcome given the mutational landscape and the lymphocyte infiltration rate 
in tumors. The work we have conducted so far, as shown a selective benefit of neo-antigens, with 
increased expansion ability and less T cell exhaustion in peripheral lymphoid organs. Also, if 
selecting tumor specific T cells in the periphery, understanding the functional state of the tumor 
specific cells will be helpful for adoptive transfer therapies. Overall, this is exciting research but 
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